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Breast cancer is currently the leading cancer and cause of cancer mortality amongst women across 
the world, including New Zealand. Despite advancement in therapeutic treatments, breast cancer 
burden remains high, with the majority of deaths reportedly caused by metastasis, where breast cancer 
cells spread to distant organs. Progression of breast cancer to metastasis requires cancer cells to 
undergo changes in their phenotypes and this is often achieved through epithelial-mesenchymal 
plasticity (EMP). During EMP, epithelial cells with apical-basal polarity and cell-cell junctions, 
gradually transition into mesenchymal-like cells with enhanced invasiveness and migratory abilities, 
which are features necessary for metastasis. Recent studies have reported that ion channels regulate 
EMP-associated cancer, including epithelial sodium channel (ENaC) that functions in sodium 
reabsorption and blood pressure regulation. The α-ENaC subunit has been suggested to play an anti-
proliferative role in breast cancer, possibly via EMP. However, the mechanism through which α-
ENaC influences EMP and breast cancer progression has not been thoroughly investigated. 
Therefore, this project aimed to study the potential role of α-ENaC in regulating EMP during breast 
cancer progression by investigating the mRNA and protein expression of EMP markers following 
overexpression of α-ENaC or inhibition of α-ENaC’s activity with amiloride. Experiments were 
conducted in the mesenchymal-like BT-549 and epithelial-like T-47D breast cancer cells using RT-
qPCR and western blot. It was hypothesised that α-ENaC overexpression will promote epithelial 
phenotypes by causing an increase in E-cadherin with a decrease in Vimentin and N-cadherin in both 
cell lines, whereas amiloride will promote mesenchymal phenotypes by reversing the changes 
expected for the overexpression experiments. Additionally, the mRNA expression of α-ENaC in both 
cell lines were also compared with RT-qPCR, while immunohistochemistry was conducted to study 




Here, I showed that epithelial-like T-47D cells have significantly higher α-ENaC expression 
compared to mesenchymal-like BT-549 cells. In support of the hypothesis, overexpression of α-ENaC 
in BT-549 and T-47D cells significantly increased E-cadherin mRNA levels, while amiloride 
significantly decreased E-cadherin in the BT-549 cells. Interestingly, Vimentin mRNA levels were 
also increased in the BT-549 cells but were not altered in the T-47D cells following α-ENaC 
overexpression. On the other hand, inhibiting α-ENaC’s activity with amiloride did not alter the 
mRNA levels of E-cadherin and Vimentin in the T-47D cells. Similarly, no significant changes were 
observed in N-cadherin mRNA levels in both cell lines with amiloride or increased α-ENaC. Despite 
changes in the EMP markers are observed at the transcriptional level, western blot was unable to 
detect E-cadherin proteins in the BT-549 cells and overexpressing α-ENaC in T-47D cells did not 
alter the protein levels of E-cadherin. 
Taken together, these results partially supported the hypothesis and showed that α-ENaC enhances 
E-cadherin gene expression, which suggest that α-ENaC may promote epithelial phenotypes in breast 
cancer cells. Furthermore, these findings also demonstrated that both α-ENaC’s expression and 
activity influences EMP. Further investigation into the role of α-ENaC and the mechanisms by which 
α-ENaC regulates EMP during breast cancer progression may potentially offer a novel therapeutic 
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1.1 Breast Cancer 
1.1.1 Epidemiology  
Breast cancer, as the most frequently diagnosed cancer and leading cause of cancer mortality amongst 
women across the world, is a major global health issue. According to the recent global cancer statistics 
produced by the International Agency for Research on Cancer (Bray et al., 2018), over 2 million 
diagnoses and 627,000 deaths were associated with breast cancer in 2018. These accounted for 11.6% 
of all cancer cases and 6.6% of all cancer-related deaths within that year (Bray et al., 2018). In well-
developed countries, the incidence rate of breast cancer is particularly high, with the Australia/New 
Zealand region having the highest age-standardised incidence rate at 94.2 per 100,000 women. 
Contrarily, less-developed countries have a higher mortality rate, with Melanesia having the highest 
age-standardised mortality rate at 25.5 per 100,000 women. Such social disparity is reportedly 
attributable to the introduction of mammography screening that allows early diagnosis as well as 
better therapeutic approaches in many well-developed countries (Hu et al., 2019). 
In New Zealand, breast cancer accounts for approximately 3300 new cancer cases every year with, 
on average, one in every nine women likely to be diagnosed with breast cancer in their lifetime 
(Ministry of Health, 2019a; Breast Cancer Foundation NZ, 2020). Furthermore, this malignancy 
contributes to over 600 deaths in New Zealand annually (Breast Cancer Foundation, 2020). Similar 
to the global breast cancer burden, health disparities in breast cancer also exist in New Zealand, with 
Māori women having an increased incidence rate and worse survival rate as compared to non-Māori 
women (Ministry of Health, 2015; Ministry of Health, 2019b). This is likely to be caused by the lack 
of accessibility to health care, such as mammography screening and cancer therapy, among the Māori 




Breast cancer, characterised by the uncontrolled proliferation of cells in the breast ducts or lobules 
(Figure 1.1), is a heterogenous disease that can be classified in various ways due to the inter- and 
intra-tumour heterogeneity in molecular phenotypes, histological features, and clinical implications 
(Saunus et al., 2013; Breast Cancer Foundation, 2020). These classifications are clinically relevant in 
predicting prognosis and individualising the treatment options for different patients (Bombardieri et 
al, 2008; Makki, 2015). 
One way of classifying breast cancer is based on the histological features of the breast tumours, such 
as the morphology, site, size, and extramammary structures (Bombardieri et al, 2008). According to 
the World Health Organisation (WHO) classification of breast cancer tumours, over 20 histological 
subtypes of in situ (pre-invasive) and invasive breast cancer were defined (Lakhani et al., 2012). Of 
these, invasive carcinoma of no special type (IC-NST), a heterogeneous group of invasive tumours 
that cannot be classified into any special type due to the manifestation of diverse features, accounts 
for the majority of the breast cancer cases (40 – 75%). Other common histological subtypes include 
ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), which are both non-invasive 
tumours found in the breast ducts or lobules (Bombardieri et al., 2008; Makki, 2015). According to 
the differentiation status of breast cancer cells, each of these subtypes can be further categorized into 
grade 1 (well-differentiated), grade 2 (moderately differentiated) and grade 3 (poorly differentiated) 
(Bombardieri et al., 2008). Such grading is based upon the assessment and scoring of the changes in 
the nuclear size and shape, the degree of tubule formation, and the mitotic activity of breast cancer 
cells (Elston & Ellis, 2002). 
In addition, breast cancer can also be molecularly classified based on the tumour’s expression of the 
progesterone receptor (PR), estrogen receptor (ER), human epidermal growth factor receptor 2 
(HER2) and the proliferation marker, Ki-67 (Kennecke et al., 2010). Four of the molecular subtypes 
that were broadly classified are the luminal A (ER-positive and/or PR-positive and Ki-67 < 14%), 
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luminal B (ER-positive and/or PR-positive and Ki-67 ≥ 14%), HER2-enriched (HER2-positive and 
ER-positive and/or PR-positive), and triple negative breast cancer (TNBC) (ER-negative, PR-
negative and HER2-negative) (Sørlie et al., 2001; Kennecke et al., 2010). Each of these subtypes has 
been shown to exhibit differences in treatment responses and clinical prognosis, with the luminal A 
subtype having a high survival rate and TNBC having a low survival rate as well as high risk of 
developing treatment resistance (Sørlie et al., 2001; Rouzier et al., 2005; Kennecke et al., 2010). 
Besides this, the Tumour-Node-Metastasis (TNM) staging system is also a common classification 
method that categorises breast cancer into stage Ⅰ, Ⅱ, Ⅲ and Ⅳ based on the progression of 
malignancy, with stage Ι as the early-stage and stage Ⅳ as the most advanced stage of breast cancer. 
In the TNM system, the size of the primary tumour (T), the number and location of lymph nodes with 
cancerous cells (N), and the metastasis status of tumours (M) are three of the parameters evaluated 
during the staging of breast cancer. Recently, in order to allow better individualisation of treatment 
options for different patients, histological grade and hormone receptor status were also incorporated 
into the TNM system (Hortobagyi et al., 2017).  
1.1.3 Treatments  
Treatment options for breast cancer are tailored to each patient based on their diagnoses and clinical 
prognosis. Typically, the optimal treatment for breast cancer is the removal of the breast tumour 
through surgical interventions such as mastectomy that removes the whole breast or breast conserving 
surgery that only removes the affected breast area (Breast Cancer Foundation NZ, 2020). Following 
surgery, in order to prevent recurrence of breast cancer, patients are often treated with radiotherapy 
or chemotherapy that utilises high doses of radiation or intravenously administered drugs to kill 
remaining cancerous cells. Based on different subtypes (Section 1.1.2), breast cancer can also be 
specifically treated with hormonal or targeted therapy that pharmacologically blocks specific 
receptors to prevent breast cancer cell growth. One example is the use of Tamoxifen, a selective ER 
regulator, to treat ER-positive breast cancer patients by inhibiting estrogen-mediated breast tumour 
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growth. Additionally, immunotherapy, a type of treatment that strengthens the patients’ immune 
system to kill cancer cells, was also recently introduced as a potential therapeutic option for breast 
cancer (Waks & Winer, 2019; Breast Cancer Foundation NZ, 2020). 
Introduction to these therapeutic approaches have significantly improved the survival rate and clinical 
outcomes of breast cancer patients in the past decades (Kaplan et al., 2015; Morrell et al., 2017), 
albeit the incidence and mortality rates of breast cancer remain high, with most of the mortality 
reportedly caused by metastasis (Jin & Mu, 2015; Bray et al., 2018).  
1.1.4 Metastasis  
Metastasis is the spread of cancer cells from the primary site of tumours to the local lymph nodes or 
distant organs. In the context of breast cancer, cancerous cells typically metastasise from the ducts or 
lobules of the breast to the lungs, liver, bones, or brain (Jin & Mu, 2015). Breast cancer patients with 
distant metastasis often have a low 5-year survival rate (27%) as compared to patients with localised 
breast cancer (survival rate ~99%) (Howlader et al., 2019). Despite the high survival rate, 30% of 
these early-stage breast cancer patients are still at risk of developing metastasis within 5 – 15 years 
following the first diagnosis (Kennecke et al., 2010). Moreover, to date, there is still no cure for 
metastatic breast cancer and current treatments are limited to symptom management (Waks & Winer, 
2019). It is therefore critical to identify the mechanisms underlying metastasis to allow development 
of possible treatments that can benefit patients with metastatic breast cancer. 
1.1.4.1 Metastatic Cascade  
Progression of breast cancer into metastasis occurs via a metastatic cascade that comprises of a series 
of steps involving cancerous cells. These include local invasion into the surrounding tissues through 
the basement membrane, intravasation into the circulatory and lymphatic systems, migration through 
the bloodstream, extravasation into the distant organs, and lastly, outgrowth and survival as secondary 
tumours within the new tissues (Figure 1.1) (Franssen et al., 2019). Various microenvironments and 
molecular barriers like the extracellular matrix (ECM) and blood-brain-barrier are involved in this 
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multi-step process. Thus, it is essential for cancerous cells to undergo changes in their characteristics 
and abilities to overcome these barriers and adapt to the foreign environments before distant 
metastasis can occur. One of the proposed mechanisms that may promote such changes and initiate 













1.2 Epithelial-Mesenchymal Plasticity (EMP)   
1.2.1 Process & Biomarkers 
EMP is a reversible process, comprising of the epithelial-mesenchymal transition (EMT) and its 
reverse process, mesenchymal-epithelial transition (MET) (Yang et al., 2020). During EMT, 
epithelial cells gradually lose their epithelial phenotypes, including apical-basal polarity, cell shape, 
Figure 1.1 Metastatic cascade. Abnormally proliferating breast cancer cells metastasise from 
the breast ducts or lobules to distant organs via the metastatic cascade during breast cancer 
progression. This cascade involves a series of steps, which include (1) local invasion into 
surrounding tissues through the basement membrane, (2) intravasation into circulatory and 
lymphatics systems, (3) migration through the blood circulation, (4) extravasation into distant 
organs, and (5) outgrowth and survival within the new tissues of distant organs. ECM = 
extracellular matrix. Chin 2020, original work based on Franssen et al., 2019. 
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as well as cell-cell junctions before acquiring mesenchymal phenotypes such as spindle-like 















As its name suggests, EMP consists of various transition states, where cells undergoing EMP are 
capable of exhibiting phenotypic plasticity by acquiring a range of intermediate phenotypes and co-
express features of both epithelial and mesenchymal cells (Figure 1.2) (Yang et al., 2020). Such 
different states of EMP can be defined by the expression of biomarkers, which are typically molecules 
that play a part in regulating EMP. Commonly, EMP is associated with a downregulation of epithelial 
markers like the cell adhesion protein, E-cadherin, as well as an upregulation of mesenchymal 
Epithelial Phenotypes 
• Normal cell shape 
• Apical-basal polarity 
• Presence of cell-cell junctions 
• Underlying basement membrane 
• Epithelial markers (e.g. E-cadherin, 
Laminin) 
Mesenchymal Phenotypes 
• Spindle-like shape 
• Loss of apical-basal polarity 
• Disassembly of cell-cell junctions 
• Degradation basement membrane 
• Highly motile & invasive 
• Mesenchymal markers (e.g. Vimentin, 
N-cadherin, Twist, Snail) 
Figure 1.2 Epithelial-mesenchymal plasticity. EMP comprises of two cellular processes, 
including EMT and the reverse process, MET. During EMT, epithelial cells gradually lose their 
cell polarity, cell-cell junction, as well as cell shape to transition into mesenchymal-like cells with 
spindle-like shape, enhanced invasiveness, and migratory abilities. Cells undergoing EMP can 
adapt a range of intermediate phenotypes, which can be defined by the expression of epithelial or 





markers like N-cadherin and the intermediate filament protein, Vimentin (Micalizzi et al., 2010; Yang 
et al., 2020). Changes in the expression of these biomarkers have been linked to the molecular 
changes occurring during EMP, including the breakdown of the basement membrane and the 
reorganisation of cytoskeletal components (Micalizzi et al., 2010). In addition to the biomarkers 
mentioned previously, transcription factors, such as Twist (Yang et al., 2004) and Snail (Smith et al., 
2014), extracellular proteins, such as Laminin (Giraldez et al., 2005), and the miR-200 family (Park 
et al., 2008) are also some of the biomarkers used to define the involvement of EMP in various cellular 
processes. 
1.2.2 Physiological Role of EMP 
EMP has long been recognised for its physiological role in embryonic development and several 
developmental processes, including gastrulation (Nakaya et al., 2008), neural crest migration (Scarpa 
et al., 2015), myogenesis (Sieiro et al., 2016), as well as the formation of cardiac valves (Ma et al., 
2005) and neurosensory organs (Kuo & Krasnow, 2015). During these developmental events, EMP 
plays a vital role in generating mesenchymal-like cells that can migrate to various parts of the embryo 
and undergo further differentiation to form specialised and functionally distinct cell types or organs 
(Micalizzi et al., 2010). In adults, EMP is also essential for tissue regeneration and wound healing 
following an inflammatory injury or ovulation (Ahmed et al., 2006; Yang et al., 2020). 
1.2.3 EMP & Cancer Progression 
EMP in adults has also been implicated in pathologies like chronic fibrosis and cancer progression 
(Yang et al., 2020). Specifically, in cancer, various studies involving EMP biomarkers have reported 
the role of EMP in cancer metastasis, with evidence showing its involvement in cellular changes 
required for the metastatic cascade such as the degradation of basement membrane and the 
disassembly of cell-cell adhesions for tumour invasion, as well as acquisition of motility for tumour-
cell migration (Wang & Shang, 2013). 
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An EMP hallmark commonly observed in cancer is the loss of E-cadherin that mediates interactions 
between epithelial cells (Wang & Shang, 2013). Such loss, which is often accompanied by the gain 
of mesenchymal markers like N-cadherin, has been detected in many advanced tumours that typically 
exhibit metastatic abilities and unfavourable prognosis, such as carcinomas of the prostate (Cheng et 
al., 1996), breast (Sarrió et al., 2008), cervix (Lee et al., 2008) and in colorectal cancers (Kim et al., 
2016). Furthermore, in vitro studies have also demonstrated that silencing E-cadherin can lead to an 
increase in the invasion and migration of prostate and colorectal cancer cells (Chunthapong et al., 
2004; Chen et al., 2012). Consistent with these findings, an in vivo study that utilised a mouse 
mammary tumour model, reported that parallel loss of E-cadherin and p53 tumour suppressor can 
promote the progression of a mammary tumour to a malignant carcinoma, that manifests similar 
features as the invasive lobular carcinoma of human breast cancer (Derksen et al., 2006). 
Howbeit, there has been conflicting evidence regarding the actual role of EMP in cancer metastasis. 
For instance, a study found higher E-cadherin expression in a metastatic gastric carcinoma (Mayer et 
al., 1993), whereas another study reported the loss of E-cadherin in non-metastatic large bowel 
tumours (Kinsella et al., 1993). It has also been reported that suppressing the mesenchymal markers, 
Twist and Snail, inhibits breast tumour metastasis (Yang et al., 2004; Smith et al., 2014), but had no 
effect on the metastasis of pancreatic tumours (Zheng et al., 2015). In turn, there was an increase in 
the drug sensitivity of the pancreatic tumours, which suggests that EMP may potentially be involved 
in other tumour functions (Zheng et al., 2015). Indeed, EMP in tumour cells has been linked to the 
development of resistance towards cell death, drug treatments, and chemotherapies in multiple studies 
(Derksen et al., 2006; Zheng et al., 2015; Wen et al., 2016; Yang et al., 2020). Such contradiction in 
the oncogenic role of EMP may be attributable to the highly variable tumour microenvironments and 
the tissue-specific actions of EMP (Micalizzi et al., 2010). 
Nevertheless, these studies confirmed that EMP is functionally significant in cancer but further 
research is required to gain a better understanding of the functions and the underlying mechanisms 
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by which EMP is involved in cancer, for the inducers or regulators of EMP to be utilised as a novel 
therapeutic target for cancer. 
1.2.4 EMP Inducers in Cancer Progression 
Multiple factors in the tumour microenvironment have been discovered to induce EMP during cancer 
progression in many studies involving cancer cell lines. As an example, the epidermal growth factor 
receptor (EGFR) has been shown to induce EMP and confer mesenchymal characteristics onto 
epithelial-like MD-AMB-468 breast cancer cells (Lo et al., 2007) and ARCaP prostate cancer cells 
(Zhang et al., 2013a). Transforming growth factor-β (TGF-β) and insulin-like growth factor (IGF) 
were also reportedly involved in inducing EMP in MCF-7 breast cancer cells and A549 lung cancer 
cells, respectively (Borowiec et al., 2007; Restrepo-Angulo et al., 2011). Other EMP inducers that 
have been identified in cancer include hypoxia, interleukin-6 (IL-6), and signalling pathways like the 
Wnt/β-catenin and Notch cascades (Davis et al., 2014).  
EMP inducers are potential therapeutic targets for cancer treatments as numerous studies have shown 
that silencing these inducers by either pharmacological inhibition or in vitro knockdown can reduce 
tumour progression (Davis et al., 2014). It is therefore crucial to identify potential new regulators and 
inducers of EMP, with recent studies suggesting that ion channels are novel EMP inducers and 
potential therapeutic targets for EMP-associated cancers (Azimi & Monteith, 2016).                                                                                         
1.3 Plasma Membrane Ion Channels  
Ion channels are transmembrane proteins that facilitate the passive transport of ions across the cell 
membrane and are integral to numerous physiological processes, including the generation of action 
potentials, pH regulation, hormone secretion, and cell volume regulation (Fermini & Priest, 2008). 
These multifunctional proteins come in various forms and they differ in their ion selectivity, 
permeabilities, gating properties, as well as activation mechanisms. Altered function and expression 
of ion channels, due to genetic mutations, may lead to a myriad of diseases, such as cystic fibrosis, 
epilepsy, and atrial fibrillation, which are collectively termed as channelopathies (Fermini & Priest, 
10 
 
2008; Azimi & Monteith, 2016). Considering the vast involvement of ion channels in multiple 
diseases, it is not surprising that approximately 19% of the currently approved drugs’ primary targets 
are ion channels and that ion channels are the main topic of discussion in studies exploring novel 
therapeutic treatments, including cancer studies (Santos et al., 2017). 
1.3.1 Role in EMP-associated Cancer Progression 
Cancer may not be categorised as a channelopathy, but defective ion channels have been extensively 
associated with cancer progression and multiple tumour cell functions, such as invasion, migration, 
and proliferation. As such, ion channels may potentially serve as novel therapeutic targets for cancer. 
However, the role of ion channels in cancer remains elusive as ion channels are showing differential 
expression in various cancers and the mechanisms by which ion channels influence cancer 
development are becoming increasingly diverse (Brackenbury et al., 2016). Among the proposed 
mechanisms, ion channels were suggested to act through EMP (Azimi & Monteith, 2016).  
A role for chloride (Cl-) channel in EMP-linked cancer was proposed by studies involving cystic 
fibrosis conductance regulator (CFTR), in which the authors showed that silencing CFTR enhanced 
the invasiveness and migratory abilities of breast and colon cancer cells. Additionally, the gain of 
mesenchymal phenotypes, such as reduced E-cadherin, increased Vimentin, and impaired cell-cell 
junctions were also observed in these CFTR-silenced cells (Zhang et al., 2013b; Sun et al., 2014).  
Contrarily, in two independent studies, downregulation of the TRP calcium (Ca2+) channels, TRPM7 
and TRPM8,  promoted epithelial phenotypes, including the gain of E-cadherin, as well as the loss of 
spindle morphology and Vimentin, in MD-AMB-231 breast cancer cells. The invasiveness and 
migratory abilities of these cells were also significantly reduced following the knockdown of TRPM7 
and TRPM8, which led to the authors suggesting an oncogenic role for Ca2+ channels in EMP-
associated cancer (Middelbeek et al., 2012; Liu et al., 2014). Besides cancer progression, a more 
recent study indicated that TRPC6, another member of the TRP family, can potentially mediate EMP 
via Ca2+ signalling and promote drug resistance in liver cancer (Wen et al., 2016).  
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Likewise, the Ca2+-activated potassium (K+) channel, KCNN4, has been suggested to promote EMP-
linked cancer as loss of KCNN4 had inhibited the migration and invasion of LoVo colorectal cancer 
cells, and concurrently led to increased E-cadherin and decreased Snail expression (Lai et al., 2013). 
Similar results were documented in a TNBC study using similar experimental methods, and on top 
of metastatic behaviours, loss of KCNN4 also suppressed breast cancer cell proliferation (Zhang et 
al., 2016). Kv10.1, a voltage-gated K+ channel, was also demonstrated to enhance the proliferation of 
MCF-7 breast cancer cells and the migration of A549 lung cancer cells following the induction of 
EMP by IGF and TGF-β, respectively (Borowiec et al., 2007; Restrepo-Angulo et al., 2011). 
Conflictingly, a recent study suggested a tumour suppressor role for Kv11.1 in TNBC, with evidence 
showing the ability of Kv11.1 in inhibiting the motility of mesenchymal-like breast cancer cells 
through the suppression of EMP (Breuer et al., 2019). Similar findings were also observed in a study 
involving the voltage-gated sodium (Na+) channel, NaV1.5. In this study, blocking NaV1.5 caused 
MD-AMB-231 breast cancer cells to lose their mesenchymal phenotypes, by which the cells became 
less invasive, more rounded, and exhibited low Snail expression (Gradek et al., 2019). 
Given the acidic tumour microenvironment, it is not surprising that the acid-sensing ion channel 
(ASIC), a voltage insensitive Na+ channel that belongs to the same superfamily as epithelial Na+  
channel (ENaC), is also involved in EMP-linked cancer. Two ASIC isoforms, ASIC1 and ASIC3 
were demonstrated to enhance acidity-induced invasion and migration of pancreatic cancer cells, and 
such changes were reversed by inhibiting ASIC1 and ASIC3. Moreover, ASIC1 or ASIC3 expression 
in pancreatic cancer cells and pancreatic tumours was also associated with an increase in Vimentin 
and Snail, as well as a decrease in E-cadherin under an acidic environment, suggesting that ASIC1 
and ASIC3 may drive acidity-induced EMP and subsequently, progression of pancreatic cancer (Zhu 
et al., 2017).  
On the other hand, preliminary data from the McDonald laboratory has recently suggested that 
inhibition of ENaC may promote breast cancer development and confer mesenchymal characteristics 
onto epithelial-like breast cancer cells (Ware & McDonald, 2020). These findings, which will be 
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further discussed in Section 1.4.3, highlight the potential role of ENaC as a novel regulator for EMP-
associated cancer. 
1.4 Epithelial Sodium Channel (ENaC) 
1.4.1 Structure, Functions & Mechanisms  
ENaC is a heterotrimeric ion channel that belongs to the ENaC/Degenerin family, which also includes 
the ASICs. Both types of channel are highly selective for Na+ ions and can be inhibited by amiloride. 
Structurally, ENaC is composed of an alpha (α), a beta (β), and a gamma (γ) subunit, which are 
encoded respectively by the SCNN1A, SCNN1B and SCNN1G genes (Hanukoglu & Hanukoglu, 
2016). In a stoichiometric ratio of 1α:1β:1γ, these subunits are assembled in a counter-clockwise 
orientation to form a narrow pore for the flow of Na+ ions across the membrane (Figure 1.3) 
(Kellenberger & Schild, 2002; Noreng et al., 2018). The α-subunit alone can also form a functional 
channel to allow transport of Na+ ions (Canessa et al., 1994b). There is also a delta (δ) subunit, which 
is encoded by the SCNN1D gene. The δ-subunit is capable of replacing the α-subunit to form a 
functional channel with β and γ subunits, but its function has not been thoroughly investigated due to 
the lack of functional expression in rodent models (Giraldez et al., 2012). Each subunit consists of 
two hydrophobic transmembrane domains, a large extracellular loop and short cytoplasmic C- and N-
terminal domains that contain PY motifs, which are essential for protein-protein interactions and 


















ENaC is predominantly expressed at the apical membrane of epithelial cells in the kidney, colon, lung, 
and reproductive tracts (Hanukoglu & Hanukoglu, 2016). As a result of the ionic gradients established 
by the Na+/K+-ATPase located at the basolateral membrane of epithelial cells, ENaC is constitutively 
active to allow the flow of Na+ ions across the epithelium. As such, it is unsurprising that this trimeric 
protein is well recognised for its functions in regulating Na+ reabsorption and modulating Na+ level 
in the extracellular fluid (ECF), which are necessary for the maintenance of salt and water 
homeostasis in the body. Moreover, ENaC is also an important mediator of many cellular processes, 
thereby regulating normal blood pressure, airway fluid volume, and ciliary transport of reproductive 
gametes (Kellenberger & Schild, 2002). 
The activity and apical expression of ENaC is tightly regulated by various factors, including 
hormones like aldosterone and vasopressin, protein kinases such as serum- and glucocorticoid-
regulated  kinase (SGK) and Akt, ubiquitin ligases like Nedd4-2 as well as proteases-mediated 
proteolytic cleavage. Such regulation is critical for the normal functioning of ENaC as channel 
dysfunction can lead to diseases such Liddle’s syndrome, a form of hypertension caused by a gain-
Figure 1.3 ENaC structure. Schematic diagram showing the arrangement of α-, ß-, and γ-
subunits in a counter-clockwise manner with a stoichiometric ratio of 1:1:1 to form a 
heterotrimeric ENaC with a pore that allows the flow of Na+ ions between the extracellular space 
and the cytoplasm. Each subunit contains two transmembrane domains, an extracellular loop, 
cytosolic N-terminal domains, and C-terminal domains that contain PY motifs. Chin 2020, original 




of-function mutation in the ENaC subunits, resulting in excessive Na+ and water reabsorption. A loss-
of-function mutation may also occur in the subunits of dysregulated ENaC, and eventually lead to 
pseudohypoaldosteronism type 1 (PHA1), which is characterised by low blood pressure (Hanukoglu 
& Hanukoglu, 2016).  
Recently, ENaC has been increasingly implicated as a mechanosensor that is capable of altering 
cellular activities like neurogenesis, migration of keratinocytes and vascular stiffening, by sensing 
changes in the external environments, possibly through its interactions with ECM components (Yang 
et al., 2013; Ashley et al., 2018; Petrik et al., 2018; Knoepp et al., 2020). Given that these changes 
are also characteristics of cancer cells and features of EMP, ENaC may potentially be involved in 
EMP and cancer (Knoepp et al., 2020). 
1.4.2 ENaC & Cancer Progression 
Various studies have suggested that ENaC may function as a pro-carcinogenic protein during cancer 
development (Xu et al., 2016). For instance, early studies reported that amiloride, an ENaC-specific 
inhibitor, is capable of reducing the growth of liver and mammary tumours, as well as suppressing 
DNA synthesis essential for glioma cell proliferation (O’Donnell et al., 1983, Sparks et al., 1983). 
The role of ENaC in the proliferation of cancer cells was later confirmed by Bondavara et al. (2009), 
who demonstrated that knocking down α-ENaC had similar effects to amiloride, wherein hypertonic 
stress-induced Na+ current and subsequent proliferation of HepG2 liver cancer cells were 
significantly reduced after silencing α-ENaC. An increase in cell volume, which is an early indication 
of apoptosis, was also observed in the α-ENaC-silenced cells (Bondavara et al., 2009). In small cell 
lung cancer (SCLC), amiloride reportedly suppressed the growth of achaete-scute homolog 1 
(ASCL1)-dependent neuroendocrine pulmonary tumours and α-ENaC was found to interact with the 
ASCL1 that produce oncogenic factors, leading to the authors suggesting that α-ENaC may contribute 
to the growth of ASCL1-dependent SCLC tumours (He et al., 2018).  
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Besides proliferation, α-ENaC has been recently demonstrated to play a role in promoting the 
metastatic progression of ovarian cancer, possibly via the induction of EMP. This is because ovarian 
cancer cells’ invasion and migration were significantly reduced following the knockdown of α-ENaC, 
and concomitantly, E-cadherin expression was also increased while the expression of Vimentin, Snail 
and N-cadherin were decreased. (Wu et al., 2019). In high grade glioblastoma multiforme brain 
tumours, α- and γ-ENaC was also shown to colocalise with ASIC1 and contribute to the amiloride-
sensitive current that enhances the migration of glioma cells (Kapoor et al., 2009; Kapoor et al., 2011). 
Additionally, the mRNA and protein expression of δ-ENaC have been detected in the human 
melanoma cells, but its function in skin cancer remains to be established (Yamamura et al., 2008).  
Contrary to the studies above, ENaC appears to exhibit tissue-specific functions in cancer progression 
as recent studies on gastric and bone cancer have suggested an anti-carcinogenic role for ENaC (Qian 
et al., 2017; Geng et al., 2020). In a gastric cancer study, β-ENaC was found to inhibit the proliferation 
and metastatic behaviours of in vitro and in vivo gastric cancer cells. Its expression was also 
associated with better survival rate, particularly in patients with advanced gastric cancer, further 
supporting the tumour suppressor function of β-ENaC in gastric cancer (Qian et al., 2017). In another 
study that was investigating the oncogenic role of miR-95 in osteosarcoma (OS), the authors showed 
that α-ENaC is negatively correlated to miR-95 and knocking down α-ENaC can eliminate the 
inhibitory effects of miR-95 inhibitor, leading to enhanced OS growth (Geng et al., 2020). 
1.4.3 ENaC & Breast Cancer 
In breast cancer, limited studies have reported on the functional role of ENaC. Despite this, ENaC 
has been previously proposed to play a role in regulating lactation in normal mammary epithelial cells 
and all ENaC subunits have been identified in cancerous mammary cell lines and tissues (Boyd & 
Náray-Fejes-Tóth, 2007). ENaC’s activity and expression were also found to be regulated by various 
hormones, including estrogen, that influences breast cancer progression (Boyd & Náray-Fejes-Tóth, 
2007; Bandara & Anjalika, 2016). Moreover, amiloride, was shown to reduce the invasive abilities 
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and proliferation of breast cancer cells (Evans & Sloan-Stakleff, 2000). In line with these findings, a 
more recent study reported that γ-ENaC may have pro-carcinogenic function and be able to promote 
breast cancer progression by enhancing inflammatory stress caused by high salt (Amara et al., 2016).  
Taking into consideration that breast cancer is a heterogenous disease, each of the ENaC subunits 
may also act differently within breast cancer (Saunus et al., 2013). Indeed, bioinformatic data that 
utilised publicly available breast cancer patients’ data showed that expression of SCNN1A, which 
encodes for α-ENaC, is higher in patients with early stage breast cancer (Reis-Filho & Pusztai, 2011). 
Using the method of Györffy et al. (2010) that assesses the association of gene expression and cancer 
prognosis, survival analysis data also showed that high α-ENaC expression correlates with better 
prognosis in breast cancer patients (Figure 1.4), while there was no significant correlation found for 
other ENaC subunits (Chin, data not shown). These findings are suggesting a protective role for α-











Figure 1.4 High expression of α-ENaC predicts better breast cancer prognosis. Survival 
analysis was performed by the author using the method developed by Györffy et al. (2010) to 
study the association of α-ENaC gene expression and prognosis of breast cancer. Red line 
represents high α-ENaC expression and black line represents low α-ENaC expression. Data 
showed that high α-ENaC expression correlates to better breast cancer survival (Chin 2020, 
original work based on Györffy et al., 2010).   
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In support of these findings, preliminary data from the McDonald laboratory has shown a significantly 
lower α-ENaC mRNA expression in mesenchymal-like breast cancer cells compared to epithelial-
like breast cancer cells (Ware and McDonald, unpublished). Moreover, in a loss-of-function 
experiment, the proliferation of breast cancer cells was significantly increased after inhibiting α-
ENaC’s expression and activity, with siRNA and amiloride, respectively (Ware & McDonald, 2020). 
This finding was not observed when ß-ENaC or γ-ENaC was knocked down, which further validate 
α-ENaC’s protective role in breast cancer (Ware & McDonald, 2020). Furthermore, α-ENaC mRNA 
expression is also correlated to higher E-cadherin and lower Vimentin expression in bioinformatic 
data analysis, suggesting that EMP may be involved in the tumour suppressor role of α-ENaC in 
breast cancer (Ware & McDonald, 2020). 
1.5 Project Rationale  
Breast cancer has been a significant health problem across the globe, including New Zealand for 
many years (Bray et al., 2018). Despite continuous efforts in reducing the health burden of breast 
cancer, there is still no definitive cure for breast cancer, and it has been challenging in developing 
treatment due to varying disease presentation (Jin & Mu, 2015). It is therefore crucial to advance the 
current understanding of breast cancer pathophysiology for improved therapeutic approaches. 
Previous work in the McDonald laboratory provided an insight into the potential role of α-ENaC in 
reducing breast cancer cell proliferation, as well as the possible involvement of EMP as the 
underlying mechanism of α-ENaC’s role in breast cancer (Ware & McDonald, 2020). However, the 
functional role of α-ENaC in breast cancer via EMP has not been thoroughly investigated. Therefore, 
this research aims to develop on the previous findings of the McDonald laboratory and further 






1.5.1 Aim & Objectives 
The aim of this project was to investigate the potential role of α-ENaC in regulating EMP during 
breast cancer progression. This was investigated through the following objectives: 
i. To investigate the ex vivo expression and distribution of α-ENaC and E-cadherin within 
human breast cancer tissues 
ii. To determine the effects of overexpressing α-ENaC and inhibiting activity of α-ENaC with 
amiloride on the mRNA expression of EMP markers, E-cadherin, N-cadherin, and Vimentin, 
in epithelial and mesenchymal breast cancer cells. 
iii. To determine the protein expression of α-ENaC and E-cadherin in epithelial and mesenchymal 
breast cancer cells following overexpression of α-ENaC  
 
1.5.2 Hypothesis 
Based on these objectives, it was hypothesised that overexpression of α-ENaC in epithelial and 
mesenchymal breast cancer cells will promote epithelial phenotype and cause an increase in the 
expression of the epithelial marker, E-cadherin, as well as a decrease in the expression of the 
mesenchymal markers, N-cadherin and Vimentin. On the other hand, it was hypothesised that 
inhibiting α-ENaC’s activity with amiloride will promote mesenchymal phenotypes and cause a 




2. Methods & Materials 
2.1 Cell Culture 
Two human breast cancer cell lines were used in this project: BT-549 and T-47D, and both were 
kindly gifted from Dr Heather Cunliffe (Department of Pathology, University of Otago). All cells 
were grown in T25 cell culture flasks (Corning, New York, USA) and maintained at 37°C with 5% 
CO2 in a humidified cell culture incubator (Forma Series II Water Jacket CO2 Incubator, Thermal 
Electron Corporation). To limit cell contamination, cell cultures and experimental set-ups were 
performed in a class two laminar flow hood in a Physical Containment level 2 laboratory. 
Additionally, to ensure a sterile experimental environment, flow hood was disinfected with 70% 
alcohol and exposed to ultraviolet light after each experiment was completed. 
2.1.1 Cell Lines & Growth Conditions 
2.1.1.1 BT-549 
BT-549 cells (ATCC® HTB-122™) are a triple negative, mesenchymal breast cancer cell line 
acquired from a 72-year-old Caucasian female with ductal carcinoma. These cells were cultured in 
filtered RPM1-1640 media (Gibco, Cat. No. 31800-022, Thermo Fisher Scientific, USA) 
supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 4.5g/L glucose, 1.5g/L sodium 
bicarbonate, 10mM HEPES, 0.8µg/mL insulin, 10% Fetal Bovine Serum (FBS) (Gibco, Cat No. 
10091-155, Thermo Fisher Scientific, NZ), and 1% penicillin streptomycin (Gibco, Cat. No. 15140-
122, Thermo Fisher Scientific, USA). 
2.1.1.2 T-47D  
T-47D cells (ATCC® HTB-133™) are a PR-positive, epithelial breast cancer cell line acquired from 
a 54-year-old female with ductal carcinoma. These cells were cultured in filtered RPM1-1640 media 
supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 4.5g/L glucose, 1.5g/L sodium 
bicarbonate, 10mM HEPES, 10% FBS, and 1% penicillin streptomycin. 
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2.1.2 Cell Thawing 
Cells were originally cryopreserved with 10% dimethyl sulfoxide (DMSO) (Thermo Fisher Scientific, 
Cat. No. BP231-100, USA) and stored long term in the -80°C freezer or indefinitely in liquid nitrogen. 
When cells were needed to set up experiments, stored cells were removed from the -80°C freezer and 
placed in a 37°C water bath for rapid thawing. Once thawed, the cells were transferred to a 15mL 
centrifuge tube (Greiner Bio-One, Cat. No. 188261, Greiner, Germany) containing 2mL of pre-
warmed growth media and the cell suspension was pelleted by centrifugation at 3.0 relative 
centrifugal force (rcf) for 3 min using a bench top centrifuge (Eppendorf centrifuge 5702, Germany). 
Following that, the supernatant was removed, and cells were resuspended in 1mL of fresh media 
before they were transferred to a T25 cell culture flask containing 8mL of media. Cells were left to 
grow in the humidified incubator until they reached 90 – 100% confluence, at which cells were 
passaged into two new flasks (Section 2.1.3). Cells were checked daily using an inverted microscope 
(Olympus, CKX41) to ensure they were growing well and not overgrown or contaminated. 
2.1.3 Cell Maintenance & Passaging 
To ensure optimal growth conditions and limit cell death due to overcrowding, cells were passaged 
once they reached 90 – 100% confluence. This was first performed by removing old media from the 
flask and adding 2mL of pre-warmed phosphate-buffered saline (PBS) (Gibco, Thermo Fisher 
Scientific, Cat No. 18912014, USA) as a washing step to remove dead cells. After removing the PBS, 
1mL of 0.25% Trypsin/1mM EDTA (Gibco, Thermo Fisher Scientific, Cat. No. 25200-056, USA) 
was added into the flask and cells were left to incubate in the humidified incubator for 5 min to allow 
cell lifting. To neutralise trypsin and prevent excessive proteolysis that may cause cell damage, 1mL 
of media was then added into the flask. Following this, cells were either transferred to a 15mL 
centrifuge tube for further cell counting (Section 2.1.4) or seeded equally into two new flasks, with 
each flask containing 8mL of fresh media.  
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If cells had not reached 90 – 100% confluence, cells were left to grow for a few more days and the 
media was changed every one to two days to ensure sufficient nutrients for cell growth as well as to 
avoid build-up of harmful metabolites. To change the media, cells were washed with 2mL of PBS 
before the cells were resuspended in 8mL of fresh media. 
2.1.4 Cell Counting & Plating 
In this project, a cell density of 2 × 105 was needed for each experimental set-up. This was achieved 
by performing cell counting with the use of a hemocytometer (Marienfeld, Cat. No. 0680010, 
Germany) before cell plating was carried out.  
Prior to cell counting, cells were washed and trypsinised by performing procedures similar to cell 
passaging detailed in Section 2.1.3. Following the neutralisation of trypsin, media containing the 
dissociated cells was transferred to a 15mL centrifuge tube and centrifuged at 3.0 rcf for 3 min using 
the bench top centrifuge. After centrifugation, supernatant was removed, and the cell pellet was 
resuspended in 1mL of media and gently pipetted up and down for homogenisation. 10µL of the 
resuspended cells were then pipetted onto the hemocytometer and the number of cells (n) within the 
central 5x5 grid was counted using an inverted microscope under 10x objective. Using Equation 2.1, 
the number of cells counted from the grids was then used to calculate the volume of cells needed to 
achieve the required cell density. Once calculated, an equal volume of cells was plated onto 35mm 
cell culture dish (Greiner Bio-One, Cat. No. 627160, Germany) that contained 2mL of media. Cells 
were subsequently incubated overnight until 60 – 70% confluence was reached before cell 
transfection (Section 2.1.5) or cell treatment (Section 2.1.6) was carried out. 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 (𝜇𝐿) =
𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 10000⁄  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 (𝑛) 10⁄
× 1000 
Equation 2.1 Equation used to calculate the volume of cells required to seed cells at a density 
of 𝟐 × 𝟏𝟎𝟓 on a 35mm cell culture dish for each experimental set-up in this project. 
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2.1.5 Cell Transfection 
2.1.5.1 DNA Plasmid 
Cell transfection is a technique that introduces foreign genetic materials into cells in order to study 
the functional role of a specific molecule by modulating its expression in the cells. 
For the gain-of-function experiments to study the role of α-ENaC in breast cancer cells, an available 
DNA plasmid that encodes for α-ENaC was not utilised for cell transfection in this project due to the 
low sensitivity of α-ENaC primary antibody present in the McDonald laboratory and thus subsequent 
unsuccessful protein detection with western blot (Appendix 2.).  
As an alternative, Hemagglutinin (HA)-tagged α-ENaC plasmid, an α-ENaC plasmid with an 
additional antigenic HA (peptide sequence: YPYDVPDYA) epitope tag attached to the C-terminal of 
α-ENaC was used to transfect the breast cancer cells. To ensure efficient gene expression, the α-
ENaC-HA plasmid was cloned into the pMT3 plasmid that contains an adenosine major late promoter 
(AdMLP) and a polyadenylation (polyA) signal (Swick et al., 1992; McDonald et al., 1995). Empty 
pMT3 plasmid was used as the transfection control. 
2.1.5.2 LipofectamineTM 3000 Transfection 
Cell transfection with the plasmids mentioned in Section 2.1.5.1 was achieved using LipofectamineTM 
3000 Transfection Reagent (Life Technologies, Invitrogen 3000 Transfection Kit, Cat. No. L3000-
015, USA). To increase transfection efficiency, cell transfection was carried out one day after cell 
plating (Section 2.1.4) to allow cells to grow to 60 – 70% confluence. 
For each transfection, 50µL of serum-free media and 3µL of LipofectamineTM 3000 were added into 
a 1.5mL micro-centrifuge tube (Multi-Max, Cat. No. MUL2941, USA), vortex mixed and incubated 
for 5 min at room temperature. During the incubation period, 50µL of serum-free media, 2µL of 
P3000 that was provided in the transfection kit, and 1µg of DNA plasmid (pMT3 plasmid with HA-
tagged α-ENaC / empty pMT3 plasmid) were added into a second 1.5mL micro-centrifuge tube and 
23 
 
vortex mixed. After 5 min of incubation, the solution in the second micro-centrifuge tube was then 
transferred to the first micro-centrifuge tube that contained LipofectamineTM 3000, vortex mixed and 
incubated for another 15 – 20 min at room temperature to allow the formation of DNA-Lipofectamine 
complexes. Following that, the media in the cell culture dish was replaced with serum-free media and 
the transfection mixture containing the DNA-Lipofectamine complexes was pipetted dropwise onto 
the dish. The cells were then incubated in the humidified incubator for 6 hours before the serum-free 
media was replaced with full growth media. At 48 hours post transfection, the transfected cells were 
either lysed for RNA extraction (Section 2.1.7) or protein isolation (Section 2.5.1).  
2.1.6 Cell Treatment 
For the loss-of-function experiments in this project, cell transfection with α-ENaC siRNA was 
originally planned to be conducted in order to study the effects of knocking down α-ENaC in the 
breast cancer cells. However, due to low transfection efficiency of the α-ENaC siRNA, amiloride, a 
specific α-ENaC blocker that inhibits the activity of α-ENaC, was used to treat the breast cancer cells. 
2.1.6.1 Amiloride  
Following cell plating (Section 2.1.4), 2µL of 5mM amiloride was administered into the media. 
Another cell culture dish containing similar number of untreated cells was used as the control. All 
cells were subsequently incubated for 48 hours before cell lysis for RNA extraction (Section 2.1.7) 
or protein isolation (Section 2.5.1) was conducted. 
2.1.7 Cell Lysis for RNA extraction 
For subsequent RNA extraction (Section 2.2), cells were lysed using TRIzol™ Reagent (Invitrogen™, 
Cat. No. 15596026, UK). At 48 hours post transfection (Section 2.1.5) or amiloride treatment 
(Section 2.1.6), media was removed from the cell culture dish and 2mL of PBS was added to wash 
the cells. After removing PBS, 200µL of TRIzol™ reagent was added onto the dish and cells were 
left to incubate for 5 min at room temperature. Following this, cell lysates were transferred to a 1.5mL 
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micro-centrifuge tube and stored in the -80°C freezer until they were needed for RNA extraction 
(Section 2.2). 
2.2 RNA Extraction 
Cell lysates were removed from the -80°C freezer and thawed for 5 min at 65°C using a digital dry 
bath incubator (Labnet, Cat. No. D1100, Taiwan). Chloroform (40µL, Thermo Fisher Scientific, Cat. 
No. BP1145-1, USA) was then added to the cell lysates and tubes were mixed by shaking vigorously 
for 15 seconds. This was followed by a 5-min incubation at room temperature before the mixture was 
centrifuged at 13.2 rcf for 15 min at 4°C to allow separation of cell lysates into three phases. The 
RNA containing aqueous phase in the upper layer was carefully collected and transferred to a new 
1.5mL micro-centrifuge tube, after which RNA extraction was performed using the Qiagen RNeasy 
Micro Kit (Qiagen, Cat. No. 74004, Germany). All procedures were carried out based on the 
manufacturer’s protocol using a refrigerated centrifuge (Eppendorf centrifuge 5415R, Germany). 
Once extracted, RNA quantification (Section 2.2.1) was performed to measure the concentration and 
purity of extracted RNA. 
2.2.1 RNA Quantification 
Concentration of extracted RNA was determined by measuring the absorbance of the samples at a 
wavelength of 260nm using the Synergy™ multi-mode microplate reader (BioTek® Instruments, Inc., 
USA). For this project, 50ng/µL of RNA sample was needed to carry out reverse transcription 
(Section 2.3) and real time-quantitative polymerase chain reaction (RT-qPCR) (Section 2.4). The 
volume of RNA samples at a concentration of 50ng/µL was calculated using Equation 2.2. and the 
RNA’s concentration measured from the microplate reader. Purity of RNA samples was assessed 
through the absorbance ratio of 260nm and 280nm (A260/A280), and an absorbance ratio of 1.8 – 
2.2 indicated high RNA purity. RNA samples with high purity were used for subsequent reverse 




𝑐1𝑣1 = 𝑐2𝑣2 
 
 
2.3 Reverse Transcription  
Following RNA quantification (Section 2.2.1), reverse transcription was performed with 
PrimeScript™ RT Reagent Kit (TaKaRa, Cat. No. RR037A, Japan) to synthesise cDNA for RT-qPCR 
(Section 2.4). 
In a 1.5mL micro-centrifuge tube, 50ng/µL of extracted RNA was added in combination with 2µL of 
5x PrimeScript Buffer, 0.5µL of reverse transcriptase enzyme, 0.5µL of Oligo dT primer, and 0.5µL 
of random hexamers, which were all provided in the kit. Milli-Q water (mqH2O) was added last to 
make up a total volume of 10µL, which was adequate for 10 RT-qPCR reactions. The mixture was 
then left to incubate for 15 min at 37°C for reverse transcription to be carried out. This was followed 
by a 5-second incubation at 85°C to inactivate the activity of the reverse transcriptase enzyme. Both 
incubation steps were conducted using the digital dry bath incubator. Following incubation, cDNA 
samples were either used for RT-qPCR (Section 2.4) or stored in the -20°C freezer for future use. 
2.4 Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) 
RT-qPCR was conducted on a 96-well plate (Multi-Max, Cat. No. MUL3890, USA) with the use of 
primers specific for human α-ENaC and EMP markers, E-cadherin, N-cadherin, and Vimentin. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers were used as the endogenous control 
and water was used as the negative control. Each experimental condition was performed in triplicate 
for each gene of interest. The sequences and manufacturing company of each primer are detailed in 
Table 2.1. All procedures were performed on ice to prevent degradation of primers or cDNA samples. 
 
 
Equation 2.2 Equation used to calculate the volume of RNA samples at a concentration of 





According to the set-up of 96-well plate shown in Figure 2.1, 0.2µL of each forward and reverse 
primer of gene of interest, 3.6µL of mqH2O, 1µL of cDNA samples, and 5µL of SYBR green 
(TaKaRa, Cat. No. RR820A, Japan) were added into each well to make up a total volume of 10µL. 











Primers Sequences Company 
α-ENaC Forward 5’-GGGTACTGCTACTATAAGCTC-3’ Sigma, USA 
α-ENaC Reverse 5’-TTGACGGTGTAATTGTTCTG-3’ Sigma, USA 
E-cadherin Forward 5’-CCGAGAGCTACACGTTC-3’ Sigma, USA 
E-cadherin Reverse 5’TCTTCAAAATTCACTCTGCC-3’ Sigma, USA 
N-cadherin Forward 5’-ACATATGATGACCGTAAC-3’ Sigma, USA 
N-cadherin Reverse 5’-TTTTTCTCGATCAAGTCCAG-3’ Sigma, USA 
Vimentin Forward 5’-GGAAACTAATCTGGATTCACTC-3’ Sigma, USA 
Vimentin Reverse 5’-CATCTCTAGTTTCAACCGTC-3’ Sigma, USA 
GAPDH Forward 5’-ACAGTTGCATGTAGACC-3’ Sigma, USA 
GAPDH Reverse 5’-TTGAGCACAGGGTACTTTA-3’ Sigma, USA 
Table 2.1 RT-qPCR primers used in this project with their primer sequences and 
manufacturing company.  
 
Figure 2.1 96-well plate set-up for RT-qPCR. For every RT-qPCR, the mRNA expression of 
each primer under two experimental conditions (α-ENaC overexpression and amiloride), 
including their controls were tested. GAPDH was used as the endogenous control. For the negative 
control (Row F and G of the 96-well plate), mqH2O was added with the master mix instead of 
RNA samples. α, E, N, V and G represents α-ENaC, E-cadherin, N-cadherin, Vimentin and 
GAPDH, respectively. OE = overexpression.  Chin 2020, original work. 
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A transparent sealing tape (Excel Scientific, Cat. No. EXCTS-RT2RR-100, USA) was then used to 
seal the top of the plate. Next, the plate was centrifuged using a mini plate centrifuge (InterLab, NZ) 
and loaded onto the Bio-Rad CFX Connect Real-Time PCR Detection System (Bio-Rad, USA) for 
quantification using the melt curve protocol designed by Dr Adam Ware from the McDonald 









Using Microsoft Excel software, data collected was first normalised to the cycle threshold (CT) values 
of endogenous control, GAPDH. Following that, the fold change in mRNA expression of the gene of 
interest relative to the fold change of the control group was calculated using Equation 2.3. 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 2−∆∆𝐶𝑇 
 
2.5 Western Blot 
Western blotting is a semi-quantitative analytical method that utilises sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins based on their molecular weight 
(MW)  prior to transferring the proteins to a solid membrane, as well as specific antibody-based probe 
Steps Temperature (ºC) Duration 




95 15 s 
3 60 60 s 
4 Repeat steps 2 – 3 40 times 
5 Annealing 65 15 s 
6 Extension 95 30 s 
Equation 2.3 Equation used to calculate the fold change in mRNA expression for the 
quantification of RT-qPCR data. 
Table 2.2 RT-qPCR melt curve protocol. Each step of the protocol was conducted using Bio-




technique to detect the protein of interest. In this project, western blotting was conducted to study the 
protein expression of E-cadherin in the breast cancer cells following overexpression of α-ENaC. 
2.5.1 Protein Isolation  
Protein isolation was conducted at 48 hours post cell transfection with α-ENaC-HA (Section 2.1.5) 
to collect protein samples for western blot.  
After media was removed and cells were washed with 2mL of PBS, 200µL of lysis buffer (Appendix 
1.) was directly added onto the cell culture dish. While on ice, the cells were left to incubate on a 
rocker (Select Bioproducts, Cat. No. LABSBS300-D-2, USA) for 10 min to allow cell lysis. The cell 
suspension was then centrifuged at 13.2 rcf for 10 min at 4°C. Following that, the supernatant was 
transferred to a new 1.5mL micro-centrifuge tube and protein yield was determined with the 
bicinchoninic acid (BCA) protein assay (Section 2.5.2). 
2.5.2 BCA Protein Assay 
The concentration of collected protein samples (Section 2.5.1) was determined by performing the 
BCA protein assay with the Bio-Rad DC Protein Assay Kit (Bio-Rad, Cat. No. 5000111, NZ) which 
consists of a reagent A, a reagent B and a reagent S. Prior to performing the BCA protein assay, 20µL 
of reagent S was added to 1mL of reagent A to make up a working reagent. 
Five dilutions of protein standard at a concentration of 0.2, 0.4, 0.6, 0.8 and 1.0mg/mL, were first 
prepared by diluting 2.0mg/mL of bovine serum albumin (BSA) (Gibco, Thermo Fisher Scientific, 
Cat. No. 30063-572, USA) (Appendix 1.) with mqH2O. Once prepared, 5µL of each protein standard 
and protein sample was pipetted in triplicate into a 96-well plate. 25µL of working reagent and 200µL 
of reagent B were subsequently added into each well that contained protein standards or samples. The 
96-well plate was then gently agitated to mix the reagents and air bubbles were removed using dry 
pipette tips.  
29 
 
After 15 min of incubation at room temperature, absorbances were measured at a wavelength of 
750nm using the Synergy™ multi-mode microplate reader. By using Microsoft Excel software, a 
standard curve was then generated by plotting the absorbances of protein standards against their 
concentration. The concentration of each protein sample was then determined using Equation 2.4, 
which was obtained from the standard curve. Following that, 30µL aliquots of protein sample, each 
containing 50µg of proteins, 6µL of 5X sample buffer and mqH2O was prepared in 1.5mL micro-








2.5.3 Polyacrylamide Gel Preparation 
The polyacrylamide gel used in this project was made up of an 8% separating gel and a 6% stacking 
gel, and these were prepared according to the recipe shown in Table 2.3. Acrylamide concentration 
was decided based on the molecular size of α-ENaC and E-cadherin. 
A gel cassette consisting of a glass plate that was pre-cleaned with ethanol, two 1.5mm spacers and 
a plastic plate was first assembled and clamped to a gel caster (Hoefer, Cat. No. SE245, USA). 
Distilled water (dH2O) was added into the gel cassette to ensure that it was well assembled and there 
was no leakage. Following this, H2O was removed and 10mL of 8% separating gel master mix was 
prepared based on the recipe outlined in Table 2.3(A) and poured into the gel cassette. The surface 
of separating gel was then overlaid with 1mL of butanol to prevent gel evaporation, to remove any 
air bubbles, and to ensure a level gel surface was formed. Separating gel was then left to set for 
approximately 1 hour at room temperature. Once the separating gel was set, butanol was removed 
using paper towels and the upper surface of separating gel was washed with dH2O. After removing 
Equation 2.4 Equation used to calculate the concentration of protein samples. From the 
standard curve generated with the absorbances and concentration of protein standards, 𝑦 
represents the absorbance of protein sample, m represents the gradient of the line in the standard 
curve, 𝑐 represents the y-intercept, and 𝑥 represents the concentration of protein sample. 
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(A) 8% Separating Gel (10mL) 
 
(B) 6% Stacking Gel (5mL) 
 
the dH2O, 5mL of 6% stacking gel master mix was prepared based on the recipe outlined in Table 
2.3(B) and poured into the gel cassette. While avoiding air bubbles formation, a 1.5mm plastic gel 
comb was then carefully inserted into the gel cassette and fixed in place with two spring clamps 
(Hoefer, Cat. No. SE252, USA). The stacking gel was then left to set for 15 min at room temperature 





2.5.4 Loading & Running SDS-PAGE 
Once the polyacrylamide gel was set, the gel comb was carefully removed and the gel cassette was 
assembled to an electrophoresis apparatus placed in a buffer chamber (Hoefer, Cat No. SE260-
10A0.75, USA). The chamber was filled with 1X running buffer (Appendix 1.). 
As a reference to estimate the molecular weight of separated proteins, 10µL of protein ladder (Bio-
Rad, Cat. No. 1610374, NZ) was first loaded into the first well. In the subsequent wells, 30µL of 
protein sample containing 50µg of proteins were then loaded from left to right. Once all protein 
samples were loaded, the electrophoresis apparatus was connected to the PowerPac™ Basic Power 
Supply (Bio-Rad, Cat. No. 1645050, USA) and the SDS-PAGE was left to run for 2 – 2.5 hours at 
120V to allow protein separation. 
Ingredients Volume 
mqH2O 4.7mL 
1.5M Tris (pH8.8) 2.5mL 
10% SDS 100µL 
30% AA 2.66mL 




0.5M Tris (pH8.8) 1.25mL 
10% SDS 50µL 
30% AA 665µL 
10% APS 25µL 
TEMED 5µL 
Table 2.3 Recipe used to prepare (A) 10mL of 8% separating gel and (B) 5mL of 6% stacking 
gel to make one polyacrylamide gel for SDS-PAGE. SDS = sodium dodecyl sulfate, AA = 
acrylamide, APS = ammonium persulfate, TEMED = tetramethylethylenediamine. 
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2.5.5 Semi-Dry Protein Transfer 
A semi-dry transfer technique was utilised in this project to transfer proteins from the polyacrylamide 
gel to the polyvinylidene difluoride (PVDF) membrane (Sigma-Aldrich, Cat. No. 3010040001, 
Germany). This technique was achieved using the Hoefer SemiPhor TE70 Transfer Unit (Amersham 
Pharmacia Biotech, Part. No. 80-6211-86, USA).  
Prior to protein transfer, the transferring anode was rinsed with dH2O and a mylar mask with an 
8cm × 7cm cutout was placed on top of the anode. A transfer stack was then prepared over the cutout 
of mylar mask. To prepare the transfer stack, six pieces of filter papers (8cm × 7cm) (Ahlstrom-
Munksjö, Cat. No. FN100, Germany) saturated with 1X transfer buffer (Appendix 1.) pre-cooled at 
4ºC, were first placed one-by-one over the cutout of mylar mask. Next, a PVDF membrane  
(8cm × 7cm) was placed in methanol for activation and subsequently soaked in pre-cooled 1X 
transfer buffer for approximately 2 – 4 min on a rocker before the activated membrane was placed on 
top of the filter papers. Following this, polyacrylamide gel loaded with protein samples, was carefully 
removed from the gel cassette and placed on top of the PVDF membrane. Lastly, another six filter 
papers (8cm × 7cm) saturated with pre-cooled 1X transfer buffer were placed one-by-one on top of 
the polyacrylamide gel. For effective protein transfer, a roller was used to remove trapped air bubbles 
when each layer of transfer stack was placed over the transferring anode.  
Once the transfer stack was prepared, approximately 1mL of 1X transfer buffer was added onto the 
transfer stack. The transferring cathode was then rinsed with dH2O and placed on top of the transfer 
stack. Semi-dry protein transfer was carried out at 45mA for 2 hours. 
2.5.6 Membrane Blocking & Antibody Incubation 
Following protein transfer (Section 2.5.5), the PVDF membrane was first cut in half to allow 
independent antibody incubation, with the upper half of membrane probed for α-ENaC-HA (MW 
~85kDa) or E-cadherin (MW ~135kDa) and the lower half of membrane probed for GAPDH (MW 
~37kDa). Once cut, both membranes were incubated in 5% non-fat milk blocking buffer (Appendix 
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1.) for 1 hour at room temperature to block non-specific binding of antibodies to the membrane. 
Following that, membranes were rinsed two times with 1X Tris-buffered saline-Tween20 (TBS-T) 
(Appendix 1.) before they were incubated in primary antibodies (Table 2.4) overnight at 4º C. 
 On the following day, primary antibody was kept in a 15mL centrifuge tube for reuse and membranes 
were washed in 1X TBS-T six times, for 5 min each to wash off remaining traces of unbound primary 
antibodies. Subsequently, membranes were incubated with an anti-rabbit horseradish peroxidase 
(HRP)-conjugated secondary antibody (Table 2.4) for 1 hour at room temperature. Another six 5-
min washes in 1X TBS-T were carried out following membrane incubation with secondary antibodies. 
All incubation steps were carried out on a rocker or orbital shaker to ensure even distribution of 




























































































































Table 2.4 Primary & secondary antibodies used for western blot. Table is detailed with blocking 
buffer, manufacturing company, catalogue number and the concentration of antibodies used to carry 
out western blot in this project. HRP = Horseradish peroxidase. 
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2.5.7 ECL Detection 
Protein bands were detected with enhanced chemiluminescence (ECL), a technique that detects 
proteins through the activity of HRP enzymes tethered to the secondary antibodies (Section 2.5.6). 
Following six 5-min washes in 1X TBS-T (Section 2.5.6), TBS-T was poured off and 600µL of each 
ECL reagent provided in the Clarity™ Western ECL Substrate kit (Bio-Rad, Cat. No. 1705060, USA) 
was added onto the membranes. Membranes were then left to incubate for 5 min at room temperature 
while containers were constantly agitated to ensure even distribution of ECL substrates across the 
membranes. After draining the membranes of ECL substrates with paper towels, membranes were 
subsequently placed between two sheets of transparent overhead projectors (OHP) in a film cassette. 
Air bubbles were removed using a roller. 
In a dark room, membranes were exposed to X-ray film (Carestream Health, Cat. No. 1651454, USA) 
and protein bands were developed by soaking the exposed film in developing solution for 
approximately 4 min, followed by a 2-min soak in fixative solution. Exposure time was adapted based 
on the intensity of proteins bands developed on the film.  
2.5.8 Membrane Stripping  
To detect multiple proteins on a single PVDF membrane, membrane stripping was performed using 
mild stripping buffer (Appendix 1.) to remove primary and secondary antibodies from the membrane 
prior to incubation with another primary antibody. For this project, membrane was stripped once, and 
all procedures were carried out on a rocker. 
After ECL detection (Section 2.5.7), the membrane was first rinsed in 1X TBS-T and incubated in 
mild stripping buffer for 10 min at room temperature. Following that, the membrane was subjected 
to three 10-min washes in 1X TBS-T to wash off remaining traces of stripping buffer and to avoid 
excessive membrane stripping. Once washed, membrane blocking, reincubation with different 
antibodies, and protein detection were performed based on the procedures described in Section 2.5.6 




Density of protein bands was analysed and quantified using ImageJ software to semi-quantitatively 
measure the protein levels of α-ENaC-HA and E-cadherin in the breast cancer cells. The calculated 
protein expression was normalised to the intensity of GAPDH protein bands. 
2.6 Immunohistochemistry (IHC) 
IHC, a semi-quantitative ex vivo technique was also performed to study the expression and 
distribution of α-ENaC and E-cadherin within breast cancer tissues. This was performed on human 
breast cancer tissues provided by Dr Tania Slatter (Department of Pathology, University of Otago) 
that were sectioned and mounted onto microscope slides by the Otago Micro and Nanoscale Imaging 
(OMNI) Unit, Department of Histology, University of Otago. The use of human tissues in this project 
had received ethical approval from the Health & Disability Ethics Committee as well as Māori 
consultations from the Ngāi Tahu Research Consultation Committee. 
2.6.1 Deparaffinisation 
Deparaffinisation was first performed by immersing the paraffin-embedded breast cancer tissue slides 
in xylene for 10 min. Next, the slides were incubated in 100% ethanol for 5 min, followed by a further 
5-min incubation in 70% alcohol for rehydration to occur. Finally, the slides were subjected to two 
2-min washes in PBS before antigen retrieval (Section 2.6.2) was performed. 
2.6.2 Antigen Retrieval 
Heat-induced epitope retrieval technique was utilised to perform antigen retrieval in this project. 
Following two washes with PBS (Section 2.6.1), slides were placed in a slide holder filled with 
sodium citrate buffer (Appendix 1.). Using a microwave, slides were heated for 2 min at full power 
and subsequently, for 10 min at half power. During the 10 min heating, the slide holder was checked 
every 2 min to ensure there was sufficient buffer covering the slides as vigorous boiling may cause 
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buffer to overflow. The slide holder was refilled with buffer if tissue slides were not fully covered by 
buffer. Following this, the slides were left to cool for approximately 1 – 1.5 hours at room temperature. 
2.6.3 Blocking & Antibody Incubation 
Once cooled, tissue sections were washed two times, for 2 min each with PBS. Following the removal 
of PBS with Kimwipes, tissue sections were outlined with a hydrophobic barrier marker (Vector 
Laboratories, Cat. No. H-4000, USA). To block endogenous peroxide activity, 300µL of 3% H2O2 
(Appendix 1.) was then added onto the outlined tissue sections and slides were left to incubate for 
20 min at room temperature. After 20 min, tissue sections were washed three times, for 5 min each 
with PBS before tissue sections were incubated with 300µL of blocking buffer (Appendix 1.) for 30 
min. This was carried out to block non-specific binding of antibody on the tissue sections. Following 
that, blocking buffer was gently knocked off the slides and tissue sections were further incubated with 
1µL of primary antibody (see Table 2.5) diluted in 100µL of blocking buffer (Appendix 1.) overnight 
at 4°C. A control slide that was running in parallel was incubated with blocking buffer without 
primary antibody. 
On the following day, primary antibody was knocked off and tissue sections were washed three times, 
for 30 seconds each with PBS. As a final washing step, tissue sections were left to sit in 100µL of 
PBS at room temperature for 10 min following the third 30-seconds wash. This was followed by a 1-
hour incubation with 4µL of anti-rabbit HRP-conjugated secondary antibody diluted in 100µL of 
blocking buffer (Appendix 1.) at room temperature. Subsequently, tissue sections were washed three 
times, for 5 min each with PBS. All incubation steps were carried out in a humidified chamber lined 






















































Tissue sections incubated with antibodies (Section 2.6.3) were stained with diaminobenzidine (DAB), 
a staining substrate that forms brown precipitates upon reaction with HRP enzymes.  
DAB and urea hydrogen peroxide tablets (Sigma-Aldrich, Cat. No. D4293, USA) were first dissolved 
in 1mL of mqH2O before the tissue sections were covered with 200µL of the DAB mixture for 
staining. Changes in the colour of DAB was monitored closely to prevent overdevelopment of DAB 
that may cause high background when observed under the microscope. Once colour was changed, 
DAB was immediately knocked off and slides were placed in mqH2O to stop the DAB reaction. Next, 
tissue sections were counterstained in hematoxylin (Sigma-Aldrich, Cat. No. HHS16, USA) for 5 
seconds to produce contrasting colour from the DAB staining for better identification of the protein 
of interest under microscope (Section 2.6.6). Excess hematoxylin was subsequently rinsed off by 
placing the slides under running water for 2 – 5 min. Following that, slides were dipped in acid alcohol 
(Appendix 1.) two times and rinsed in Scott’s water (Appendix 1.) for 1 min. Slides were then briefly 
rinsed for a final time under running water. 
Table 2.5 Primary & secondary antibodies used for IHC. Table is detailed with manufacturing 
company; catalogue number and antibody concentration use to carry out IHC in this project. HRP 
= Horseradish peroxidase. 
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Next, dehydration procedures were performed by immersing the slides in the following sequence: 70% 
alcohol for 10 min, 100% alcohol for 8 min with one change at 4 min, and xylene for 10 min. 
Following that, sections were mounted with dibutylphthalate polystyrene xylene (DPX) mountant 
(Sigma-Aldrich, Cat. No. 06522, USA) and a coverslip glass (Corning, Cat. No. 2975-244, New York, 
USA). Slides were left to air dry overnight before immunohistochemical detection (Section 2.6.6) 
was carried out. 
2.6.6 Immunohistochemical Detection & Quantification  
A confocal microscope (Olympus, BX61, OMNI) was used to visualise and identify the presence of 
α-ENaC or E-cadherin on the stained tissue slides, which was indicated by brown staining. Once 
identified, photographs of the region of interest were taken with 10x, 20x, and 40x objective lens. 
Density of brown staining in each image was quantified and analysed using ImageJ software. 
2.7 Statistical Analysis 
All statistical analyses were performed on GraphPad Prism 8 (GraphPad Software, San Diego, USA) 
and data are expressed as mean±standard error of mean (SEM). ‘N’ indicates number of biological 
repeats or sample size and ‘n’ indicates number of replicates carried out for each sample. For RT-
qPCR and western blot, an unpaired Student t-test with Welch’s correction for unequal variances was 
performed to determine the significant differences in the mean relative expression of each gene or 
protein of interest. A one sample t-test was used to compare α-ENaC mRNA expression in BT-549 
and T-47D breast cancer cells for the RT-qPCR data, as well as to determine the significant 
differences in the mean density of α-ENaC-HA protein bands in both cell lines. Results were 





The aim of this project was to investigate the potential role of α-ENaC in regulating EMP during 
breast cancer progression. To address this aim, immunohistochemistry (IHC) was initially performed 
to study the ex vivo expression and distribution of α-ENaC and E-cadherin within human breast cancer 
tissues (Section 3.1). However, due to low sensitivity of antibodies and limited availability of breast 
cancer tissues, the ex vivo role of α-ENaC was not further explored and this project focused on 
investigating the in vitro role of α-ENaC using mesenchymal-like BT-549 and epithelial-like T-47D 
breast cancer cells. 
mRNA expression of α-ENaC in the BT-549 and T-47D breast cancer cells were first compared using 
RT-qPCR (Section 3.2). Following that, the effects of increasing α-ENaC’s expression and inhibiting 
α-ENaC’s activity with amiloride on the mRNA levels of EMP markers, E-cadherin, N-cadherin, and 
Vimentin in both cell lines were investigated with RT-qPCR (Section 3.3 & 3.4). Additionally, 
western blot was performed to further investigate the effects of overexpressing α-ENaC on the protein 
levels of the epithelial marker, E-cadherin in both cell lines (Section 3.5). It was hypothesised that 
increasing α-ENaC expression will promote epithelial phenotypes and cause an increase in E-cadherin 
as well as a decrease in N-cadherin and Vimentin in both epithelial and mesenchymal breast cancer 
cells. Contrarily, amiloride will promote mesenchymal phenotypes, and cause a decrease in E-









3.1 Ex vivo expression of α-ENaC and E-cadherin in human breast 
cancer tissues 
The initial plan for this project was to investigate the ex vivo expression of α-ENaC and E-cadherin 
within human breast cancer tissues using IHC. IHC was performed with the DAB staining technique 
(see Section 2.6.4) that produces brown staining upon detection of the protein of interest via an 
interaction with the HRP-conjugated secondary antibody. Four experiments have been performed and 
for each experiment, three tissue sections were used, including one negative control tissue section 
that was stained without primary antibody and two tissue sections that were stained for either α-ENaC 
or E-cadherin using the antibodies mentioned in Section 2.6.3. Confocal microscope was 
subsequently used to visualise the stained tissue slides. Figure 3.1 shows representative IHC images 
of the breast cancer tissue sections taken under 10x, 20x, and 40x magnification. 
Analysis of these sections identified no intense brown staining in the breast cancer tissue sections that 
were probed with α-ENaC (Figure 3.1D-F) or E-cadherin (Figure 3.1G-I) primary antibody, 
suggesting that α-ENaC and E-cadherin may not be expressed in human breast cancer tissues. 
However, preliminary data from the McDonald laboratory (Ware & McDonald, 2020) and several 
breast cancer studies (Singhai et al., 2011; Fulga et al., 2015) have previously demonstrated that α-
ENaC and E-cadherin are expressed in human breast cancer tissues, which indicate that the negative 
results could also be caused by technical problems associated with the IHC protocol performed in this 
project (Section 2.6). With further replication of experiments, it was observed that the colour of DAB 
mixture did not change during the immunostaining procedure (see Section 2.6.4), suggesting that the 
antibodies used to carry out IHC for this project were not effective and the antibody staining did not 
work. To confirm the effectiveness of antibodies, western blot was performed with protein samples 
collected from breast cancer cell lines that were known to express α-ENaC and E-cadherin.  
Firstly, in the protein samples that were incubated with the same α-ENaC primary antibody that were 
used for IHC, no visible α-ENaC protein bands were detected and the blots showed high background 
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staining with multiple non-specific protein bands (Appendix 2.), indicating that the α-ENaC antibody 
was ineffective. In turn, E-cadherin protein bands were successfully detected in the breast cancer cells 
(see Section 3.5.2) when the same E-cadherin antibody was used, suggesting that other technical 
problems, which will be further discussed in Section 4.1, may have also contributed to the negative 
results. However, due to limited availability of human breast cancer tissues, the IHC protocol could 
not be further optimised and thus, the ex vivo expression of α-ENaC and E-cadherin in breast cancer 
tissue was not further explored. The focus of this project was shifted to investigating the in vitro role 







Figure 3.1 Expression of α-ENaC and E-cadherin were not detected in the breast cancer 
tissues. Representative IHC images of breast cancer tissue sections that were stained (A-C)  
without primary antibody (negative control), and with (D-F) α-ENaC or (G-I) E-cadherin primary 
antibody. No brown staining was observed in all the breast cancer tissue sections, suggestive of 
unsuccessful protein detection. Images were taken under 10x (left column), 20x (middle column) 
and 40x (right column) magnification using a confocal microscope. Scale bar = 20µm, 10µm and 




3.2 α-ENaC mRNA expression in the mesenchymal-like BT-549 and 
epithelial-like T-47D breast cancer cells 
The in vitro role of α-ENaC in regulating EMP during breast cancer progression was first studied by 
comparing α-ENaC mRNA expression in the mesenchymal-like BT-549 and epithelial-like T-47D 
breast cancer cells using RT-qPCR. RNA was extracted from both cell lines and RT-qPCR was 
performed using α-ENaC primers. After normalising the data to respective GAPDH data, the fold 
change in mRNA levels of T-47D cells was normalised to the fold change of BT-549 cells. Using one 
sample t-test for comparison, the mRNA expression of α-ENaC was found to be significantly higher 
(p<0.05) in the T-47D epithelial cells as compared to the BT-549 mesenchymal cells (N=3) (Figure 
3.2), indicating that high α-ENaC expression is associated with less invasive breast cancer cells that 












Figure 3.2 Epithelial-like T-47D breast cancer cells have higher α-ENaC mRNA expression 
compared to mesenchymal-like BT-549 breast cancer cells. RNA was extracted from wild-type 
BT-549 and T-47D breast cancer cells, and RT-qPCR was performed with α-ENaC primers to 
compare the endogenous mRNA expression of α-ENaC in both cell lines, with the data normalised 
to respective GAPDH. Data are shown as fold change relative to the normalised α-ENaC mRNA 




3.3 Effects of overexpressing α-ENaC on the mRNA levels of EMP 
markers in breast cancer cells using RT-qPCR 
Following the comparison of α-ENaC mRNA expression in the breast cancer cells, the role of α-
ENaC in regulating EMP was further investigated by transfecting the BT-549 and T-47D breast 
cancer cells with an α-ENaC-HA gene cloned into the pMT3 plasmid to assess the effects of 
increasing α-ENaC expression on the mRNA levels of EMP markers. Cells that act as the control 
group were transfected with pMT3 plasmid. Cells were lysed 48 hours post transfection and RNA 
was extracted from the transfected breast cancer cells. RT-qPCR was then performed with α-ENaC, 
E-cadherin, N-cadherin, and Vimentin primers. After normalising the data to GAPDH, unpaired 
Student t-test with Welch’s correction was used to determine the statistical significance in the mean 
fold change in mRNA levels of α-ENaC and EMP markers relative to their respective control. 
3.3.1 Overexpression of α-ENaC increased mRNA levels of E-cadherin 
& Vimentin in BT-549 mesenchymal breast cancer cells 
Firstly, in the BT-549 mesenchymal breast cancer cells with overexpressed α-ENaC (N=5), there was 
a significant upregulation in the α-ENaC mRNA levels (p<0.05) compared to the control group 
(Figure 3.3A), confirming that the cell transfection with α-ENaC-HA plasmid was successful. 
Overexpression of α-ENaC significantly increased the mRNA levels of E-cadherin (p<0.05), with an 
approximately 1.4-fold increase in mean fold change relative to the control group (Figure 3.3B). This 
result supported the hypothesis. A significant increase was also observed in the mRNA levels of 
Vimentin (p<0.05), but there was only 0.2-fold increase in mean fold change relative to the control 
cells (Figure 3.3D), suggesting that the significant differences could be due to small variation in the 
mean fold change and not an effect caused by increased α-ENaC expression. On the other hand, there 
was an approximately 0.8-fold increase in the mean fold change of N-cadherin mRNA levels, but no 
statistically significant differences were found between the BT-549 cells with overexpressed α-ENaC 
and the control group (p>0.05) (Figure 3.3C).   
43 
 
Figure 3.3 Relative fold change in mRNA expression of α-ENaC and EMP markers in the 
BT-549 mesenchymal breast cancer cells with overexpressed α-ENaC. RNA was extracted 
from the BT-549 cells transfected with pMT3 (Control) or α-ENaC-HA (α-ENaC OE) plasmid 48 
hours after transfection. RT-qPCR was then performed with α-ENaC and EMP marker primers to 
assess the mRNA expression of (A) α-ENaC, (B) E-cadherin, (C) N-cadherin and (D) Vimentin 
in the presence of increased α-ENaC, with data normalised to GAPDH and control experiments. 
Data expressed as mean±SEM. Unpaired Student’s t-test with Welch’s correction, N=5, n=3. *p 

























3.3.2 Overexpression of α-ENaC increased mRNA levels of E-cadherin 
and Vimentin in T-47D epithelial breast cancer cells 
A significant increase in α-ENaC mRNA levels (p<0.001) was also observed in the T-47D epithelial 
breast cancer cells with overexpressed α-ENaC (N=3) (Figure 3.4A), confirming that the cell 
transfection with α-ENaC-HA plasmid in T-47D cells was successful. Similar to the BT-549 cells 
(Section 3.3.1), E-cadherin mRNA levels were significantly upregulated (p<0.05) after increasing α-
ENaC expression in T-47D cells, with an approximately 2.2-fold increase in the mean fold change 
relative to the control cells (Figure 3.4B). This finding is in line with the hypothesis. Contradictorily, 
the mean fold change in mRNA levels of N-cadherin and Vimentin in the T-47D cells showed an 
average increase by 5.2-fold and 8.9-fold, respectively following overexpression of α-ENaC (Figure 


































Figure 3.4 Relative fold change in mRNA expression of α-ENaC and EMP markers in the 
T-47D epithelial breast cancer cells with overexpressed α-ENaC. RNA was extracted from the 
T-47D cells transfected with pMT3 (Control) or α-ENaC-HA (α-ENaC OE) plasmid 48 hours 
after transfection. RT-qPCR was then performed with α-ENaC and EMP markers primers to assess 
the mRNA expression of (A) α-ENaC, (B) E-cadherin, (C) N-cadherin and (D) Vimentin in the 
presence of increased α-ENaC, with data normalised to GAPDH and control experiments. Data 
expressed as mean±SEM.  Unpaired Student’s t-test with Welch’s correction, N=3, n=3. *p<0.05, 





3.4 Effects of amiloride on the mRNA levels of EMP markers in breast 
cancer cells using RT-qPCR 
To further validate α-ENaC’s role in regulating EMP, BT-549 mesenchymal and T-47D epithelial 
breast cancer cells were treated with amiloride to assess the effects of inhibiting α-ENaC’s activity 
on the mRNA levels of EMP markers. Cells were lysed after 48 hours and RNA was extracted from 
the amiloride-treated cells as well as the untreated cells that serve as the control group. RT-qPCR was 
then performed with α-ENaC, E-cadherin, N-cadherin, and Vimentin primers. After normalising data 
to GAPDH, unpaired Student t-test with Welch’s correction was used to determine the statistical 
significance in the mean fold change in mRNA levels of α-ENaC and EMP markers relative to their 
respective control. 
3.4.1 Inhibiting α-ENaC’s activity with amiloride decreased mRNA 
levels of E-cadherin and Vimentin in BT-549 mesenchymal breast 
cancer cells 
Firstly, in the BT-549 mesenchymal breast cancer cells (N=5), no significant changes were observed 
in the mRNA levels of α-ENaC following amiloride treatment (p>0.05) (Figure 3.5A). This is likely 
to be due to amiloride only blocks the activity of α-ENaC and does not alter the endogenous 
expression of α-ENaC in the breast cancer cells. Despite this, blocking α-ENaC’s activity with 
amiloride significantly decreased the mRNA levels of E-cadherin (p<0.05) and Vimentin (p<0.05), 
with an approximately 0.3-fold and 0.2-fold decrease in mean fold change relative to the control 
group, respectively (Figure 3.5B & D). These findings are in contrast with the results observed in 
the BT-549 cells with overexpressed α-ENaC (Section 3.3.1) and downregulation of E-cadherin 
mRNA levels supported the hypothesis. On the other hand, consistent with the overexpression 
experiments (Section 3.3.1), there was no statistically significant differences in the mRNA levels of 























Figure 3.5 Relative fold change in mRNA expression of α-ENaC and EMP markers in the 
BT-549 mesenchymal breast cancer cells following amiloride treatment. RNA was extracted 
from both untreated (Control) and amiloride-treated BT-549 cells (Amiloride) 48 hours after 
treatment. RT-qPCR was performed with α-ENaC and EMP marker primers to assess the mRNA 
expression of (A) α-ENaC, (B) E-cadherin, (C) N-cadherin and (D) Vimentin following inhibition 
of α-ENaC’s activity with amiloride, with data normalised to GAPDH and control experiments. 
Data expressed as mean±SEM. Unpaired Student’s t-test with Welch’s correction, N=5, n=3. *p 




3.4.2 Inhibiting α-ENaC’s activity with amiloride did not alter the 
mRNA levels of EMP markers in T-47D epithelial breast cancer cells 
In line with the findings of amiloride-treated BT-549 cells (Section 3.4.1), the mRNA levels of α-
ENaC between the amiloride-treated T-47D epithelial breast cancer cells and the control cells (N=3) 
were not significantly different (p>0.05) (Figure 3.6A). However, contrary to the BT-549 cell lines, 
no significant change was observed in E-cadherin mRNA levels (p>0.05) after treating the T-47D 
cells with amiloride (Figure 3.6B). This finding was unexpected and did not support the hypothesis. 
On the other hand, there was an average increase by 2.2-fold and 1.5-fold in the mean fold change of 
N-cadherin and Vimentin mRNA levels in the amiloride-treated T-47D cells relative to the control 
cells (Figure 3.6C & D), but both of these findings were not statistically significant (p>0.05). Overall, 
the qPCR results showed that treating the T-47D cells with amiloride to inhibit α-ENaC’s activity 













Figure 3.6 Relative fold change in mRNA expression of α-ENaC and EMP markers in the 
T-47D epithelial breast cancer cells following amiloride treatment. RNA was extracted from 
both untreated (Control) and amiloride-treated T-47D cells (Amiloride) 48 hours after treatment. 
RT-qPCR was performed with α-ENaC and EMP marker primers to assess the mRNA expression 
of (A) α-ENaC, (B) E-cadherin, (C) N-cadherin and (D) Vimentin following inhibition of α-
ENaC’s activity with amiloride, with data normalised to GAPDH and control experiments. Data 



























3.5 Effects of overexpressing α-ENaC on the protein levels of E-
cadherin in breast cancer cells using western blot 
Given that the mRNA expression and activity of α-ENaC was shown to alter the mRNA levels of E-
cadherin in the breast cancer cells, western blotting was subsequently performed to further investigate 
the effects of increasing α-ENaC expression on the protein levels of E-cadherin in the cells. This was 
carried out to confirm the role of α-ENaC in regulating E-cadherin as E-cadherin at the mRNA and 
protein level may be regulated by different mechanisms in the breast cancer cells. 
Protein lysates were collected from the BT-549 and T-47D breast cancer cells 48 hours after cells 
were transfected with an α-ENaC-HA gene cloned into the pMT3 plasmid for overexpression of α-
ENaC or pMT3 plasmid (control group). These cells were set-up and transfected in parallel with the 
breast cancer cells used to perform RT-qPCR to allow comparison of the changes caused by 
overexpression of α-ENaC at the mRNA and protein level. Protein samples were subsequently loaded 
into the polyacrylamide gel at an amount of 50µg to allow protein separation with SDS-PAGE. 
Following semi-dry protein transfer, α-ENaC and E-cadherin proteins in the cells were detected using 
the specific anti-HA and anti-E-cadherin antibodies mentioned in Section 2.5.6 as well as the ECL 
technique. Due to low sensitivity of α-ENaC primary antibody, HA primary antibody was used to 
detect α-ENaC and to confirm whether the overexpression was successful. Density of protein bands 









3.5.1 E-cadherin proteins were not detected in BT-549 mesenchymal 
breast cancer cells 
α-ENaC-HA protein bands were detected at approximately 85kDA (Sigma-Aldrich Co, 2015; Cheung 
et al., 2019), in the protein samples harvested from the BT-549 cells transfected with α-ENaC-HA 
plasmid (N=5) (Figure 3.7A). Moreover, densitometry results showed little variation in the cell 
transfection efficiency (Figure 3.7B), confirming that the overexpression of α-ENaC in the BT-549 
cells was successful. However, E-cadherin protein bands, which were expected to be detected at 
approximately 135kDa (Liu et al., 2019; Cell Signalling Technology, 2020), were not detected in all 
the protein samples harvested from BT-549 cells, including the control group (Figure 3.7C). One 
possible reason is the low efficiency of semi-dry transfer method in transferring E-cadherin protein 
with high molecular weight (~135kDa), resulting in incomplete protein transfer and low protein signal. 
This was confirmed by a member of the McDonald laboratory, who performed wet protein transfer 
method and successfully detected E-cadherin proteins in the BT-549 cells (McQueen, data not shown). 
Albeit, due to time constraints, attempts at detecting protein expression of E-cadherin in the BT-549 











Figure 3.7 Effects of overexpressing α-ENaC on the protein levels of E-cadherin in the BT-
549 mesenchymal breast cancer cells. Protein lysates were collected from the BT-549 cells that 
were either transfected with α-ENaC-HA plasmid for overexpression of α-ENaC (α) or pMT3 
plasmid to serve as the control group (c). Western blotting was carried out with anti-HA or anti-
E-cadherin primary antibody to detect α-ENaC and E-cadherin proteins in the BT-549 cells. 
GAPDH were used as the protein loading control. (A) Representative western blot showing 
presence of α-ENaC-HA proteins at ~85kDa, indicative of successful α-ENaC overexpression. (B) 
Density of α-ENaC-HA protein bands were quantified and normalised to their respective loading 
control with densitometry to show the variability of transfection efficiency. Data was obtained 
from pooled data (two independent western blot) and expressed as mean±SEM. One sample t-test, 
N=5, **p<0.01. (C) Representative western blot showing no E-cadherin proteins detected in the 





3.5.2 Overexpression of α-ENaC did not alter E-cadherin protein levels 
in T-47D epithelial breast cancer cells 
In the T-47D epithelial breast cancer cells, successful overexpression of α-ENaC  was confirmed with 
the detection of α-ENaC-HA protein bands at approximately 85kDA (Sigma-Aldrich Co, 2015; 
Cheung et al., 2019), in the protein samples harvested from the T-47D cells transfected with α-ENaC-
HA plasmid (N=3), while no band was detected in the control cells (N=3) (Figure 3.8A). In contrast 
to the BT-549 cells, E-cadherin protein bands were detected in the T-47D cells at approximately 
135kDa (Figure 3.8B) (Liu et al., 2019; Cell Signalling Technology, 2020). However, there were no 
significant differences found in the protein levels of E-cadherin between the T-47D cells with 
overexpressed α-ENaC and the control cells (N=3, p>0.05) (Figure 3.8D), suggestive that increasing 















Figure 3.8 Effects of overexpressing α-ENaC on the protein levels of E-cadherin in the T-
47D epithelial breast cancer cells. Protein lysates were collected from the T-47D cells that were 
transfected with α-ENaC-HA plasmid for overexpression of α-ENaC (α) or pMT3 plasmid to serve 
as the control group (c). Western blotting was carried out with anti-HA or anti-E-cadherin primary 
antibody to detect α-ENaC and E-cadherin proteins in the T-47D cells. GAPDH were used as the 
protein loading control. Representative western blot showing presence of (A) α-ENaC-HA and 
(B) E-cadherin proteins in the T-47D cells. Density of protein bands were quantified and 
normalised to their respective loading control with densitometry. (C) Relative density of α-ENaC-
HA protein bands to show the variability of transfection efficiency. Data was obtained from pooled 
data (three independent western blot). One sample t-test, N=3. **p<0.01. (D) Relative density of 
E-cadherin protein bands in the T-47D cells with overexpressed α-ENaC as compared to the 





















ENaC is an amiloride-sensitive, heterotrimeric Na+ ion channel found at the apical surface of many 
epithelia, including kidney, colon, lung, and mammary tissues. As an important regulator of Na+ 
reabsorption, ENaC is well recognized for its physiological role in numerous cellular processes such 
as regulating blood pressure and airway fluid volume (Hanukoglu & Hanukoglu, 2016). Recently, 
ENaC has been increasingly implicated in the progression of various cancers, and each subunit has 
been shown to exert different roles in different types of cancer (see Section 1.4.2). In breast cancer, 
preliminary data from the McDonald laboratory has suggested an anti-proliferative role for the alpha 
subunit of ENaC, with evidence showing a significant increase in the proliferation and viability of 
breast cancer cells following the knockdown of α-ENaC or amiloride-mediated inhibition of α-
ENaC’s activity. In contrast, overexpression of α-ENaC resulted in a significant decrease in breast 
cancer cell proliferation (Ware & McDonald, 2020). Moreover, survival analysis data showed that 
high α-ENaC expression is linked to favourable prognosis in breast cancer patients (Figure 1.4), 
further suggesting that α-ENaC has a protective role in breast cancer. 
EMP, a transitional process that involves epithelial cells changing their phenotypes to transform into 
mesenchymal-like cells, and vice versa, has been extensively reported to drive the progression of 
cancer into metastasis by conferring invasive features and migratory abilities onto cancer cells, 
allowing the cells to metastasise to distant organs (Micalizzi et al., 2010; Yang et al., 2020). Various 
factors in the tumour microenvironment were shown to induce EMP during cancer progression and 
recently, ion channels, including α-ENaC have emerged as a novel inducer or regulator for EMP (see 
Section 1.3.1) (Azimi & Monteith, 2016; Wu et al., 2019). With these findings and the discovery of 
a significantly higher α-ENaC expression in the epithelial breast cancer cells as compared to the 
mesenchymal breast cancer cells, the McDonald laboratory proposed that α-ENaC may potentially 
exhibit its anti-proliferative role in breast cancer by regulating EMP (Ware & McDonald, 2020). 
Using the bioinformatic tools that analyse data from breast cancer patients, the McDonald laboratory 
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also demonstrated a positive correlation between the expression of SCNN1A gene that encodes for 
α-ENaC with increased epithelial marker, E-cadherin as well as decreased mesenchymal marker, 
Vimentin (Ware & McDonald, 2020). These are features associated with the occurrence of EMP 
during cancer progression, which further suggest that EMP may be involved in the proposed role of 
α-ENaC in breast cancer. Albeit, to the best of my knowledge, changes in the markers of EMP have 
not been experimentally assessed with changes in α-ENaC’s expression or activity. 
This research project was therefore undertaken to build on the findings from the McDonald laboratory 
and further explore the potential role of α-ENaC in regulating EMP during the progression of breast 
cancer. It was hypothesised that α-ENaC will promote epithelial phenotypes in the breast cancer cells 
through the regulation of EMP markers. To study this aim, this project has investigated the effects of 
increasing α-ENaC’s expression, as well as blocking α-ENaC’s activity with amiloride on the mRNA 
expression of E-cadherin, Vimentin, N-cadherin and E-cadherin protein expression in two 
phenotypically different breast cancer cell lines: mesenchymal-like BT-549 cells and epithelial T-
47D cells. The mRNA and protein levels of EMP markers were investigated with RT-qPCR and 
western blot, respectively. Additionally, IHC was performed to study the ex vivo expression of α-











4.1 Ex vivo expression of α-ENaC and E-cadherin in human breast 
cancer tissues 
This project initially investigated the ex vivo expression of α-ENaC and E-cadherin within human 
breast cancer tissues with IHC. A specific antibody-based probe technique and DAB that forms brown 
staining upon interaction with the antibody, were utilised for the detection of α-ENaC and E-cadherin 
in the cancerous tissues.  
Using a confocal microscope for observation,  no intense brown staining was observed on two of the 
breast cancer tissue sections that were probed for α-ENaC and E-cadherin (Figure 3.1), indicating 
that α-ENaC and E-cadherin expression were not detected in the stained breast cancer tissues. As a 
change in the colour of the DAB mixture was not observed during immunostaining procedure (see 
detailed method in Section 2.6.4), low sensitivity of primary antibody was suggested to be the cause 
that led to unsuccessful protein detection in the tissues. By performing western blot technique using 
the same α-ENaC primary antibody on four different breast cancer cell lines (Appendix 2.), the α-
ENaC primary antibody was confirmed to be non-functional as no α-ENaC protein bands were 
detected in all of the breast cancer cell lines, including the cell lines (MCF-7 and T-47D) that were 
known to express α-ENaC (Jiang et al., 2019). Moreover, the blots also showed high background 
staining with multiple non-specific protein bands, indicative of an ineffective primary antibody was 
used (Bass et al., 2017) (Appendix 2.). However, other aspects in the IHC protocol may have also 
contributed to the negative results as the same tube of E-cadherin primary antibody was used to 
perform western blotting for this project and E-cadherin proteins were successfully detected in the 
breast cancer cells (see Section 3.5.2).  
Thus, to identify the underlying cause, optimisation of IHC protocol was performed with further 
replication of experiments. Some of the technical aspects that were addressed include adjusting the 
pH of sodium citrate buffer, using fresh xylene to deparaffinise tissue slides, and increasing antibody 
incubation period. However, there was still no DAB staining observed in the breast cancer tissue 
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sections. Due to limited availability of human breast cancer tissue sections, other possible technical 
problems that have been considered, such as low antibody concentration, non-functional DAB tablets, 
over- or under-heating of tissue sections during antigen retrieval, were not able to be further optimised. 
Therefore, the ex vivo expression of α-ENaC and E-cadherin in human breast cancer tissues were not 
further explored for this project. 
Although the current project was not able to detect α-ENaC and E-cadherin in human breast cancer 
tissues, many immunohistochemical studies involving carcinomas obtained from patients with 
different breast cancer subtypes, have identified E-cadherin expression at the membrane of the 
epithelial cells in breast tumours. The expression of E-cadherin was also reported to be reduced or 
absent in majority of the metastatic tumours (Moll et al., 1993; Singhai et al., 2011; Fulga et al., 
2015). These findings are not surprising as loss of E-cadherin, a cell adhesion molecule that plays a 
vital role in maintaining the adhesions between epithelial cells, has been shown to promote the 
breakdown of intercellular junctions as well as cell polarity, allowing cancer cells to detach from the 
primary tumours and migrate to distant organs (Wang & Shang, 2013; Fulga et al., 2015). Indeed, 
loss of E-cadherin is often associated with an increase in the invasiveness and metastatic abilities of 
various cancer cell lines, including breast cancer cells (Yang et al., 2003; Tryndyak et al., 2010) 
Similar to E-cadherin, α-ENaC expression has also been discovered in the epithelial cells of human 
breast cancer tissues by the McDonald laboratory (Ware & McDonald, 2020), albeit to my knowledge, 
no studies have further investigated α-ENaC expression in human breast cancer tissues. Given that α-
ENaC was shown to regulate E-cadherin in vitro (Section 4.2 & 4.3), it would be of much interest to 
further explore the ex vivo expression of α-ENaC and E-cadherin, as well as the correlation between 
two of these proteins using different subtypes of breast cancer tumours in future studies. Taking into 
consideration that α-ENaC may have a protective role in breast cancer, , a correlation of loss of α-
ENaC in parallel with loss of E-cadherin is expected to be observed in malignant breast tumour, such 
as the invasive ductal carcinoma that was reported to have low E-cadherin expression (Fulga et al., 
2015).   
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4.2 Higher α-ENaC mRNA expression in epithelial-like T-47D cells 
As the ex vivo role of α-ENaC was not further explored, the focus of this project shifted to investigate 
the in vitro role of α-ENaC in regulating EMP using two phenotypically different breast cancer cell 
lines: mesenchymal-like BT-549 and epithelial-like T-47D cells. This was first studied by comparing 
the endogenous expression level of α-ENaC mRNA in both breast cancer cell lines using RT-qPCR.  
The McDonald laboratory has previously shown that α-ENaC expression was significantly reduced 
in the mesenchymal breast cancer cells (Ware & McDonald, 2020). Consistent with their finding, 
results from the current study showed that T-47D cells with epithelial phenotypes have significantly 
higher α-ENaC mRNA expression as compared to the BT-549 cells with mesenchymal phenotypes 
(Figure 3.2). This finding further confirmed that high α-ENaC expression is associated with less 
invasive and non-metastatic breast cancer cells that exhibit epithelial phenotypes. Moreover, despite 
that in vivo expression of α-ENaC in human breast tumours, to the best of my knowledge, has not 
been investigated, a breast cancer study has performed microarray analysis and showed that high α-
ENaC gene expression is correlated to lower grade and less invasive breast cancer (Ko et al., 2013). 
Similar results were found in an unpublished local study using bioinformatic data, and on top of that, 
a significant reduction in α-ENaC gene expression was also reported in the most aggressive form of 
breast cancer, TNBC (unpublished data).  
Along with the survival analysis data that demonstrated a positive correlation between α-ENaC gene 
expression and high survival rates in breast cancer patients (Figure 1.4), these findings suggest that 
α-ENaC has a protective role in breast cancer and EMP may potentially be involved. To confirm this, 
gain- and loss-of-function experiments were subsequently conducted to determine whether α-ENaC 





4.3 Impacts of α-ENaC on the mRNA levels of EMP markers in breast 
cancer cells using RT-qPCR 
To gain an insight into the functional role of α-ENaC in regulating EMP, the second objective for this 
project was to determine if α-ENaC has an impact on the EMP markers at the transcriptional level in 
the mesenchymal-like BT-549 and epithelial-like T-47D breast cancer cells. For this purpose, gain- 
and loss-of-function experiments were conducted using the highly sensitive quantitative technique, 
RT-qPCR to quantify the mRNA levels of EMP markers.   
4.3.1 Effects of α-ENaC overexpression on the mRNA levels of EMP 
markers in breast cancer cells 
For the gain-of-function experiments, RT-qPCR was performed with BT-549 and T-47D cells that 
were transfected with α-ENaC-HA plasmid to observe whether overexpressing α-ENaC will alter the 
mRNA levels of E-cadherin, N-cadherin, and Vimentin in the breast cancer cells. Of note, considering 
that α-ENaC alone can form functional Na+ channel (Canessa et al., 1994b), it was expected that 
overexpressing α-ENaC will cause more functional channels to be present in the cells. 
With the use of bioinformatic data that involved dataset from breast cancer patients, the McDonald 
laboratory previously reported that α-ENaC gene expression is positively correlated to increased E-
cadherin expression (Ware & McDonald, 2020). In support of this finding, the current project showed 
that overexpressing α-ENaC significantly upregulated E-cadherin mRNA levels in both 
mesenchymal-like BT-549 and epithelial-like T-47D breast cancer cells (Figure 3.3B & 3.4B). A 
significant increase in α-ENaC mRNA levels was also observed in both cell lines with overexpressed 
α-ENaC when compared to control cells (Figure 3.3A), suggesting that the gain in E-cadherin was a 
result of successful α-ENaC overexpression. Therefore, this finding supported my hypothesis that 
increasing α-ENaC expression can potentially enhance E-cadherin expression and promote epithelial 
phenotypes in breast cancer cells. Given that E-cadherin was suggested to exhibit a tumour suppressor 
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role and its expression is correlated to non-malignant and less invasive breast tumours (Younis et al., 
2007; Singhai et al., 2011), this finding further supported our hypothesis that α-ENaC has a protective 
role in breast cancer, possibly through reducing EMP. 
The intermediate filament protein, Vimentin and the cell adhesion molecule, N-cadherin, are both 
common mesenchymal markers that have been suggested to facilitate the collective migration of 
cancer cells to distant organs through the maintenance of the connectivity and adhesions between the 
migrating cells (Kokkinos et al., 2007; Micalizzi et al., 2010). During EMP,  loss of Vimentin and 
N-cadherin expression is often coupled to a gain in E-cadherin expression, and vice versa in many 
cancer studies (Zhu et al., 2017; Wu et al., 2019). In the current study, Vimentin mRNA levels were 
shown to increase significantly in parallel with the E-cadherin mRNA levels in the BT-549 
mesenchymal cells after increasing α-ENaC expression (Figure 3.3D). This result was unexpected 
and contradicted the findings from the previous studies. Howbeit, as the differences in the fold change 
of Vimentin mRNA levels between the BT-549 cells with overexpressed α-ENaC and the control 
cells were relatively small, this significant result could also be due to small variation between samples 
and not a result of overexpressing α-ENaC. On the other hand, no significant alterations was observed 
in the mRNA levels of Vimentin in the T-47D epithelial cells (Figure 3.4D) as well as the mRNA 
levels of N-cadherin in both cell lines (Figure 3.3C & 3.4C) following overexpression of α-ENaC. 
The findings on the mesenchymal markers contradicted my hypothesis that increasing α-ENaC 
expression will decrease mRNA levels of N-cadherin and Vimentin in the breast cancer cells. 
Overall, the findings from the gain-of-function experiments suggested that increasing α-ENaC 
expression in the BT-549 and T-47D breast cancer cells that exhibit different phenotypes, enhanced 
the expression of epithelial marker, E-cadherin, but did not alter the expression of mesenchymal 




4.3.2 Effects of amiloride on the mRNA levels of EMP markers in breast 
cancer cells 
Knocking down α-ENaC via siRNA transfection was initially planned for the loss-of-function 
experiments in this project but this was not performed due to low transfection efficiency of the siRNA. 
Amiloride is an established ENaC/Degenerin Na+ channel blocker that can selectively inhibit α-
ENaC’s activity by binding to a specific site on α-ENaC (Ismailov et al., 1997; Kelly et al., 2003). 
Prior to this project, the McDonald laboratory has shown that amiloride can produce comparable 
effects as knocking down α-ENaC in the cells, whereby both conditions had enhanced the 
proliferation of breast cancer cells to a similar extent (Ware & McDonald, 2020). Hence, in the loss-
of-function experiments for the current project, BT-549 mesenchymal and T-47D epithelial breast 
cancer cells were treated with amiloride to assess whether blocking the activity of α-ENaC affects the 
mRNA levels of E-cadherin, N-cadherin, and Vimentin in the breast cancer cells.  
In both BT-549 and T-47D cell lines, no significant differences in the α-ENaC mRNA levels were 
found between the amiloride-treated cells and the control cells (Figure 3.5A & 3.6A), suggestive that 
amiloride only acts by blocking the channel’s activity and has no effects on the endogenous 
expression of α-ENaC in the breast cancer cells. Similar results were reported by a previous Honours 
student from the McDonald laboratory, whereby no noteworthy changes were observed in the mRNA 
levels of α-ENaC after treating the mesenchymal-like BT-549 and MD-AMB-231 breast cancer cells 
with amiloride (McQueen, 2018).  
Despite lack of changes in α-ENaC expression, amiloride caused a significant reduction in the mRNA 
levels of E-cadherin and Vimentin, with no changes in the N-cadherin levels in the BT-549 cells 
(Figure 3.5B, C &D). These results are not likely to be caused by non-specific action of amiloride 
as the concentration of amiloride (2µM) that was used for this project is an optimal concentration to 
block ENaC whereas a higher concentration of amiloride is required to block other Na+ channels, 
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such as the Na+/H+ exchanger (Kleyman & Cragoe, 1988). This confirmed that blocking α-ENaC’s 
activity with amiloride can affect the expression of EMP markers in the breast cancer cells.  
Contrary to the BT-549 cells, no significant changes were observed in the mRNA levels of all EMP 
markers after treating T-47D cells with amiloride (Figure 3.6B, C & D). This could possibly be due 
to small sample size was used for the T-47D experiments and large variation in the fold change 
expression of EMP markers between samples. 
Nevertheless, a downregulation in the E-cadherin expression in the BT-549 cells following amiloride 
treatment had partially supported my hypothesis that amiloride will lead to a decrease in the 
expression of epithelial marker in the breast cancer cells. Moreover, the changes in E-cadherin and 
Vimentin expression caused by amiloride may indicate that α-ENaC’s activity is also potentially 
involved in regulating EMP during breast cancer progression, albeit further studies are required to 
confirm this. 
4.3.3 Possible explanation for the changes in the mRNA levels of 
mesenchymal markers following α-ENaC overexpression & amiloride 
treatment 
Given that α-ENaC was shown to suppress breast cancer cell proliferation and its expression was 
significantly upregulated in the epithelial breast cancer cells (Ware & McDonald, 2020), it was 
hypothesised that α-ENaC will promote epithelial phenotypes, indicated by increased E-cadherin as 
well as decreased N-cadherin and Vimentin in the breast cancer cells. However, the results observed 
in the expression of mesenchymal markers, N-cadherin and Vimentin contradicted the hypothesis, 
wherein no significant changes was observed in N-cadherin and Vimentin mRNA expression in the 
T-47D epithelial cells that were overexpressed with α-ENaC or treated with amiloride. In the BT-549 
mesenchymal cells, Vimentin mRNA levels significantly increased and decreased following 
overexpression of α-ENaC and amiloride treatment, which was similar to the changes seen in the 
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mRNA levels of E-cadherin in the BT-549 cells. One of the possible reasons for these results is the 
dynamic nature of the EMP process. 
It is important to note that EMP is not an “all or nothing” process where cells completely transform 
from an epithelial state to a mesenchymal state, but rather a dynamic process that comprises of a 
range of intermediate states, in which cells undergoing incomplete or partial EMP can acquire hybrid 
phenotypes by exhibiting both epithelial and mesenchymal features (Figure 4.1) (Yang et al., 2020). 
Hybrid phenotypes allow cells to gain migratory abilities while maintaining cell-cell adhesions for 
collective migration, and thus, the hybrid state of EMP is often observed in the circulatory tumour 
cells (CTC) as well as invasive cancer cell lines and metastatic tumours (Micalizzi et al., 2010; Liao 
& Yang, 2020). As an example, E-cadherin and Vimentin were shown to concurrently express in the 
invasive breast tumours (Yamashita et al., 2018). Considering that E-cadherin plays an important role 
in assembling and maintaining the intercellular adhesion (Fulga et al., 2015), this finding is not 
surprising as E-cadherin may be contributing to the outgrowth of breast tumours at the distant organs 
by forming cell-cell junctions. Indeed, a study has generated a human mammary epithelial cell culture 
model that expressed both epithelial and mesenchymal characteristics, and showed that hybrid EMP 
state is critical for migrating breast cancer cells to invade new tissues and outgrowth as secondary 
tumours in the distant organs (Kröger et al., 2019). A skin cancer study also reported that TGF-β, a 
common EMP inducer, promoted the invasiveness and metastatic abilities of cancerous epidermal 
cells while retaining the expression of E-cadherin in the cells (Janda et al., 2006). Based on these 
reports in the literature, the findings presented in this thesis could be interpreted as suggesting that 
overexpression of α-ENaC in the breast cancer cells had only partially suppressed EMP, leading to 
the occurrence of incomplete EMP and breast cancer cells displaying hybrid phenotypes.  
Furthermore, even though the role of E-cadherin as a tumour suppressor as well as an epithelial 
marker has been well established, there are growing evidence suggesting that post-EMT cancer cells 
can re-express E-cadherin after migrating to the distant organs, possibly via MET (Liao & Yang, 
2020). This was first suggested by Chao et al. (2010) who discovered that E-cadherin expression was 
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higher in the breast tumours collected from the metastatic site as compared to the breast tumours 
collected from the primary tumour site. Additionally, upregulated E-cadherin expression was also 
observed in the mesenchymal-like breast cancer cells that were cultured with hepatocytes in a tumour-
like microenvironment, further confirming the occurrence of E-cadherin re-expression at the 
metastatic site (Chao et al., 2010). High E-cadherin expression was also seen in the metastatic 
tumours of thyroid cancer (Nakamura et al., 2014). These findings suggested that E-cadherin may 
also play a role in the metastatic progression of cancer by promoting the outgrowth of tumour cells 
at the distant metastatic site (Chao et al., 2010; Nakamura et al., 2014). This was supported by another 
breast cancer study that utilised mouse mammary tumour model and demonstrated the involvement 
of E-cadherin in different stages of the metastatic cascade, during which E-cadherin exhibits varying 
roles. In this study, loss of E-cadherin was shown to enhance the invasiveness of breast tumour cells, 
while decreasing the metastasis and formation of tumour cell colonies, leading to the authors 
proposing that E-cadherin may concomitantly act as a suppressor of tumour invasion and a promoter 
of tumour metastasis in breast cancer (Padmanaban et al., 2019). As such, it is possible that 
overexpressing α-ENaC in the mesenchymal-like BT-549 cells had caused E-cadherin to exert its 
metastatic promoter role, rather than suppressing EMP. This can explain the concurrent increase and 
decrease in E-cadherin and Vimentin expression in the BT-549 cells following α-ENaC 
overexpression and amiloride treatment, which were observed in this project.  
In addition, another common characteristic of EMP during cancer progression is the cadherin 
switching, where loss of E-cadherin is accompanied by a gain in N-cadherin expression (Micalizzi et 
al., 2010). This feature is often seen in the cancer cells that are undergoing EMP in order to progress 
into mesenchymal-like cells (Micalizzi et al., 2010) and it is typically associated with the malignant 
tumours of various cancers (see Section 1.2.3). However, this may not always be the case for breast 
cancer as studies have shown that changes in E-cadherin expression is independent of N-cadherin 
expression in the cancer cells. For example, Hazan and colleagues (2000) reported that 
overexpressing N-cadherin enhanced the invasiveness and migratory abilities of the epithelial-like 
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MCF-7 breast cancer cells while E-cadherin expression in the cells were not altered. Similar results 
were observed in another breast cancer study that utilised BT-20 epithelial cells, and on top of that, 
increasing E-cadherin expression in the mesenchymal-like MD-AMB-435 cells had no effects on the 
morphology and invasiveness of the cells (Nieman et al., 1999). These studies suggested that the 
expression and activity of N-cadherin are not dependable on E-cadherin, and a parallel change in E-
cadherin and N-cadherin expression is not necessary for EMP to occur during breast cancer 
progression (Nieman et al., 1999; Hazan et al., 2000). These findings could possibly explain the non-
significant changes observed in N-cadherin expression despite a significant alteration in E-cadherin 
expression after increasing α-ENaC expression and inhibiting α-ENaC’s activity in both BT-549 and 














Figure 4.1 EMP hybrid state. EMP is a dynamic process that comprises of a range of 
intermediate states, during which cells undergoing EMP can adapt a spectrum of phenotypes, 
including hybrid phenotype. Acquisition of hybrid phenotypes typically occurs during partial or 
incomplete EMP and it involves cells exhibiting features of both epithelial and mesenchymal 
cells. Such state of EMP has been shown to play a role in promoting the outgrowth of breast 
cancer cells within new tissues after metastasising to distant organs. Chin 2020, original work 





4.4 Effects of α-ENaC overexpression on the protein levels of E-
cadherin in breast cancer cells using western blot 
After discovering that α-ENaC’s expression affects the transcriptional levels of E-cadherin in two 
phenotypically different breast cancer cell lines, it is of great interest to find out if the increase in 
transcriptional levels caused an increase in the translation of the E-cadherin mRNA into protein and 
upregulated the protein population of E-cadherin in the breast cancer cells. For this reason, semi-
quantitative method, western blot was employed to investigate the effects of increasing α-ENaC 
expression on the protein levels of E-cadherin in the breast cancer cells. To match the effects of α-
ENaC overexpression on the mRNA and protein levels of E-cadherin (see Section 3.3 & 4.3.2), BT-
549 and T-47D cells that were used for RT-qPCR and western blotting, were concurrently set-up and 
transfected with α-ENaC-HA plasmid. Successful overexpression of α-ENaC in BT-549 and T-47D 
cells was confirmed with the detection of α-ENaC-HA protein bands in the protein samples collected 
from the cells that were transfected with α-ENaC-HA plasmid (Figure 3.7A & 3.8A).  
Firstly, in the BT-549 mesenchymal cells, no E-cadherin protein bands were detected in any of the 
protein samples collected from the cells with overexpressed α-ENaC and the control cells (Figure 
3.7C). To determine if this was a result of technical problems, further replications were performed 
using different amount of protein samples or varying concentration of E-cadherin antibody. However, 
there were still no E-cadherin protein bands detected in the BT-549 cells. It was later suggested that 
the semi-dry transfer method (see Section 2.5.5) may not be effective in transferring high molecular 
weight protein, such as E-cadherin (MW ~135kDa), resulting in an incomplete protein transfer. This 
was suggested when a member of the McDonald laboratory showed successful detection of E-
cadherin protein bands in the BT-549 cells using wet protein transfer method (McQueen, data not 
shown). However, due to time constraints, attempts at detecting E-cadherin proteins in the BT-549 
cells using wet-transfer method were not made in this project and therefore, effects of α-ENaC 
overexpression on the protein expression of E-cadherin in the BT-549 cells could not be explored. 
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In addition to technical limitations, unsuccessful detection of E-cadherin proteins in the BT-549 cells 
could also be due to low to no E-cadherin expression in the mesenchymal breast cancer cells. This is 
not surprising considering that E-cadherin is an epithelial marker and loss of E-cadherin is often 
associated with mesenchymal-like cancer cell lines (Chunthapong et al., 2004; Chen et al., 2012). In 
support of this, multiple breast cancer studies have performed western blotting and reported negative 
E-cadherin expression in the majority of the mesenchymal breast cancer cell lines, including BT-549 
cells (Tryndyak et al., 2010; Jiang et al., 2019).  
Contrary to the BT-549 cells, E-cadherin protein bands were detected in the T-47D cells (Figure 
3.8C), indicative of high E-cadherin expression in the epithelial breast cancer cells. However, 
densitometric analysis of the protein bands showed no significant differences in the E-cadherin 
protein levels between the T-47D cells with overexpressed α-ENaC and the control cells (Figure 
3.8D). As successful overexpression of α-ENaC was confirmed at both the mRNA and protein levels, 
this result is likely to suggest that increasing α-ENaC expression in the T-47D cells had no effects on 
the protein levels of E-cadherin, which contradicted my hypothesis. Of note, this result is also limited 
by the smeared GAPDH (protein loading control) protein bands (Figure 3.8C), and thus the 
normalisation and quantification of the E-cadherin protein bands may not be completely accurate.  
Previous studies reported that E-cadherin has a relatively short half-life of approximately 5 hours as 
it is essential for constant turnover of E-cadherin to maintain a coordinated assembly of intercellular 
junctions between the epithelial cells (Shore & Nelson, 1991; de Beco et al., 2009). In line with these 
findings, a study has utilised three different EMP cellular models and showed that loss of E-cadherin 
proteins, mainly via endocytosis, often occurs at early stages of EMP while transcriptional loss of E-
cadherin occurs during the late stages of EMP (Janda et al., 2006). This could possibly explain why 
E-cadherin protein expression in the T-47D cells did not change despite that there was a significant 
increase in the mRNA levels of E-cadherin following overexpression of α-ENaC. However, the 
western blot technique used in this project only measured total cellular E-cadherin proteins and did 
not separate cell surface E-cadherin, that would presumably be part of the intercellular junctions, 
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from intracellular E-cadherin. As such, there may a possible change in the cell surface E-cadherin as 
suggested above, but this was not able to be detected with western blotting in this project. Future 
studies can confirm this by performing cell surface biotinylation assay or immunocytochemistry to 
assess the cell surface expression of E-cadherin in the breast cancer cells following α-ENaC 
overexpression or amiloride treatment. 
Overall, the western blot results showed that increasing α-ENaC expression in the T-47D epithelial 
cells does not affect the protein levels of E-cadherin and E-cadherin protein expression was not 
detected in the BT-549 mesenchymal cells. 
4.5 Limitations & Future Directions 
4.5.1 Breast Cancer Cell Lines & Tissues 
For this project, mesenchymal-like BT-549 and epithelial-like T-47D breast cancer cells were used 
to account for the phenotypic differences when investigating the impacts of α-ENaC on EMP markers. 
However, over 80 human breast cancer cell lines have been identified to date (Dai et al., 2017) and 
each cell line often exhibits differential characteristics in terms of morphology, cellular phenotypes, 
regulatory mechanisms, hormonal and treatment responses (see Section 1.1.2). As such, the 
functional impacts of α-ENaC that were discovered in this project may not be observed with other 
breast cancer cell lines. Future studies can possibly involve additional breast cancer cell lines with 
different phenotypes from the BT-549 and T-47D cells to observe if α-ENaC produces similar or 
different effects on the EMP markers in other breast cancer cell lines. Using normal breast epithelial 
cell lines like MCF-10A to compare the impacts of α-ENaC under non-cancerous and cancerous 
conditions is also an interesting option for future project. 
Similarly, in addition to limited availability of human breast cancer tissues, the subtype of breast 
cancer tissues used to perform IHC in this project was not known, which limited the investigation of 
the ex vivo expression of α-ENaC and E-cadherin as certain types of breast cancer tissues may not 
express the protein of interests (see Section 4.1). If IHC for this project was successful, a 
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collaboration with a pathologist to identity the type of breast tumours by which α-ENaC or E-cadherin 
are found in can be carried out for future studies.  
4.5.2 Slow cell growth & small sample size 
Due to slow growth of T-47D epithelial breast cancer cells and time constraints, the T-47D cells were 
not at optimal confluency (<50%) when the cells were being passaged, transfected, or treated with 
amiloride. Hence, the findings on T-47D cells may be limited by low transfection or treatment 
efficiency, as well as low amount of lysate samples used for experimentation. For the same reason, 
only three sets of T-47D cells were used to conduct RT-qPCR and western blotting. This sample size 
is considered small and the results may be limited by reduced power of study. This could possibly 
explain the non-significant results which were observed in the experiments involving T-47D cells. 
4.5.3 Amiloride 
As mentioned previously, knocking down α-ENaC for the loss-of-function experiments was not 
performed due to ineffective siRNA. Of note, this siRNA that was initially planned to be used was a 
new lot of siRNA but was tested to be ineffective by a member of the McDonald laboratory and thus, 
it was not used for this project. Although amiloride has been shown to produce comparable effects in 
enhancing breast cancer cell proliferation, it is still not known how downregulating α-ENaC 
expression in the breast cancer cells affects the EMP markers considering that amiloride does not 
alter the endogenous expression of α-ENaC. Therefore, it would be a great interest to perform 
knockdown experiments in the breast cancer cells with a new sample of siRNA for future studies. 
Furthermore, as the amiloride used for this project has been previously utilised by other members of 
the McDonald laboratory for experiments, current measurement was not performed to confirm the 
functional status of amiloride or to determine if amiloride had successfully inhibited the activity of 
α-ENaC in the breast cancer cells. Although ineffective inhibition of α-ENaC’s activity is not likely 
to occur given that changes in the EMP markers were observed in the amiloride-treated breast cancer 
cells, electrophysiology experiments such as Ussing chamber and patch-clamp recording can be 
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performed in parallel with the in vitro experiments in future studies to confirm the effects of amiloride 
as well as to assess the treatment efficiency. 
4.5.3 Non-functional antibodies 
Another methodological limitation of this project was the non-functional α-ENaC primary antibody 
that led to unsuccessful detection of α-ENaC proteins in human breast cancer tissues (Section 3.1) 
and breast cancer cells (Appendix 2.). For this reason, the ex vivo expression of α-ENaC was not 
further explored and a change of project plan was made to transfect the breast cancer cells with HA-
tagged α-ENaC plasmid. This was to allow detection of α-ENaC with anti-HA primary antibody 
during western blotting. 
4.5.5 α-ENaC threshold 
As this project was conducted primarily based on the preliminary findings from the McDonald 
laboratory and there are currently limited studies researching on this topic, this project is limited by 
the fact that the minimum and maximum threshold to increase α-ENaC expression in order to see an 
effect on the expression of EMP markers is not known. Moreover, the optimal parameters to transfect 
the cells for overexpression, including the transfection duration and amount of DNA used for 
transfection, are unclear. Considering that only E-cadherin expression had significantly changed in 
this project, it is possible that greater α-ENaC overexpression is required to see an effect. On the 
contrary, there is also a possibility that the large increase in α-ENaC mRNA expression following α-
ENaC overexpression has triggered stress responses in the breast cancer cells and activated other 
stress-related signalling mechanisms that may influence the expression of EMP markers. 
4.5.6 Future Directions 
This research project was highly affected by inadequate time to perform a complete experiment, 
resulting in experimentation with small sample size and limited parameters. As such, in the near future, 
the next step would be to increase the sample size of the T-47D cells to confirm any significant 
differences between samples, and to investigate the effects of overexpressing α-ENaC and amiloride 
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on the protein expression of the mesenchymal markers, N-cadherin and Vimentin, that were not able 
to be investigated in this project. Likewise, it would also be an option to study the mRNA and protein 
expression of EMP markers that were not explored in this project, such as Snail, Twist, and Laminin. 
Additionally, it was suggested that negative E-cadherin expression in the BT-549 mesenchymal cells 
could be due to ineffective semi-dry protein transfer method, but this was not optimised with wet 
transfer method due to time constraints. Future studies can attempt at using wet transfer method to 
detect E-cadherin protein expression in the mesenchymal breast cancer cells that were known to 
express less E-cadherin (Tryndyak et al., 2010; Jiang et al., 2019). 
The qPCR results on the effects of α-ENaC overexpression and amiloride on the mRNA expression 
of EMP markers had raised the possibility of α-ENaC being functionally involved in incomplete EMP 
and conferring hybrid phenotypes onto breast cancer cells. Moreover, as the α-ENaC threshold to see 
a complete effect on EMP markers was unclear, future studies can investigate the mRNA expression 
of EMP markers at different time points following overexpression of α-ENaC and amiloride treatment. 
Simultaneously, investigating the effects of knocking down α-ENaC with siRNA on the mRNA and 
protein levels of EMP markers would also be an option. Although α-ENaC alone can form a functional 
channel (Canessa et al., 1994b) and previous findings showed that only α-ENaC has an impact on the 
proliferation of breast cancer cells (Ware & McDonald, 2020), it is still an interesting option to 
determine if overexpressing and knocking down other individual subunits (β, γ and δ) as well as αβƴ 
subunit together affect the expression of EMP markers in different breast cancer cell lines. 
To gain further insight into the role of α-ENaC in regulating EMP, functional experiments such as 
invasion and migration assay can also be conducted in vitro and in vivo to observe for changes in the 
invasiveness and migratory abilities of the transfected or treated breast cancer cells. In addition, it 
would also be an interesting option to perform cell surface biotinylation assay or 
immunocytochemistry to see how increasing or decreasing α-ENaC expression and amiloride affects 
the cell surface expression of E-cadherin and other EMP markers that are located at the cell surface. 
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Lastly, due to time constraints and limited availability of human breast cancer tissues, the ex vivo 
expression of α-ENaC and E-cadherin within human breast cancer tissues could not be explored. 
Given that α-ENaC was discovered in breast cancer tissues and that EMP markers have been shown 
to differentially express in breast tumours, it would be interesting to collaborate with a pathologist 
and further explore the ex vivo expression of α-ENaC as well as the markers for epithelial and 
mesenchymal phenotypes within different subtypes of breast cancer tissues in future studies. 
 
5. Conclusion 
Taken together, this research project demonstrated that α-ENaC is highly expressed in less invasive 
epithelial-like breast cancer cells and increasing α-ENaC’s expression may enhance the mRNA 
expression of E-cadherin in both mesenchymal-like BT-549 and epithelial-like T-47D breast cancer 
cells. These findings suggest that α-ENaC can potentially suppress EMP during breast cancer 
progression by conferring epithelial phenotypes onto breast cancer cells. Moreover, this project also 
presents findings that α-ENaC’s activity may be functionally involved in the regulation of EMP in 
breast cancer, further suggesting that α-ENaC has a role in breast cancer, albeit more studies are 
essential to confirm the functional significance of α-ENaC in breast cancer. Nevertheless, the findings 
from this project provide an insight into the mechanism through which α-ENaC influences breast 
cancer progression as well as the functional role of α-ENaC as a novel regulator of EMP. Further 
research on α-ENaC’s role in EMP may potentially offer novel therapeutic target for breast cancer, 
considering breast cancer burden, particularly metastasis, has been increasing over the years, despite 
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Appendix 1. Buffer Recipe 
 
 











- 2.94g Tri Sodium Citrate 
- 1L mqH20 
- 500µL TWEEN® 20 





- 30mL 30% H2O2 





- 4% BSA 
- 2% NGS 
- 10mL PBS 
 
 
Acid Alcohol - 0.25mL Concentrated HCl 
- 100mL 100% Ethanol 
 
 
Scott’s Water - 10g MgSO4 
- 2g NaHCO3 
















- 100µL 10X TBS 
- 10µL Triton X-100  
(Bio-Rad, Cat. No. 16010407, NZ) 
- 1µL Leupeptin 
- 1µL Pepstatin A 
- 1µL PMSF 







- 0.02g BSA 





- 192mM Glycine 
-  24mM Tris 
- 0.5% SDS (w/v) 
 
1L of 1X solutions: 
100mL 10X Running 
Buffer  




- 129mM Glycine 
- 25mM Tris 
- 20% Methanol 
 
1L of 1X solutions: 
200mL 5X Transfer 
Buffer + 800mL dH2O 
Table 7.1 IHC & western blot buffer recipe. Table is detailed with concentration of materials 





- 20mM Tris 
- 150nM Sodium Chloride 
- pH7.5 
 
1L of 1X TBS-T: 
100mL 10X TBS  
+ 1mL TWEEN® 20 
 (Sigma-Aldrich, Cat. No. 
P2287, Germany) 
+ 899mL dH20 
 
5% Non-fat Milk 
Blocking Buffer 
- 2.5g Non-fat Milk Powder 






- 200mM Glycine 
-  0.1% SDS 
- 1% TWEEN® 20 




























Figure 7.1 Representative western blot showing unsuccessful detection of α-ENaC proteins 
in four different breast cancer cell lines when α-ENaC primary antibody was used. Protein 
samples collected from four different breast cancer cell lines, including the mesenchymal-like 
cells, BT-549 and MD-AMB-231, as well as the epithelial-like cells, T-47D and MCF-7 cells. 
were obtained from a member of the McDonald laboratory. These cells were used to test the 
effectiveness of α-ENaC primary antibody with western blot. No α-ENaC protein bands were 
detected in all breast cancer cells, including the T-47D and MCF-7 cells that were known to 
express α-ENaC. Moreover, developed blot showed high background with numerous non-specific 
protein bands, further suggesting that the α-ENaC primary antibody used to perform IHC in this 
project was non-functional. N=1 for each cell line. 
 
Appendix 2. Western blot showing ineffectiveness of α-ENaC primary 
antibody in detecting α-ENaC proteins in breast cancer cells 
 
 
